Abstract: Type 2 Diabetes Mellitus (T2DM) is a chronic disease which corresponds to 90% of the worldwide cases of diabetes, mainly due to epigenetic factors such as unhealthy lifestyles. First line therapeutic approaches are based on lifestyle changes, most of the time complemented with medication mostly associated with several side effects and high costs. As a result, the scientific community is constantly working for the discovery and development of natural therapeutic strategies that provide lower financial impact and minimize side effects. This review focus on these nature-based therapeutic strategies for prevention and control of T2DM, with a special emphasis on natural compounds that present pharmacological activity as dipeptidyl peptidase-4 (DPP4), alpha-amylase, alpha-glucosidase, lipase, and protein tyrosine phosphatase 1B (PTP1B) inhibitors.

Keywords: type 2 diabetes mellitus; phytopharmacology; dipeptidyl peptidase-4 (DPP4); alpha-amylase; alpha-glucosidase; lipase; protein tyrosine phosphatase 1B (PTP1B)

1. Introduction

Diabetes mellitus (DM) is a chronic disease characterized by excessive concentration of sugar glucose in the bloodstream, a pathophysiological sign termed: hyperglycemia [1]. There are two main types of DM: type 1 (T1DM) caused by the absence of insulin production due to auto-immune mediated loss of pancreatic β-cells and type 2 (T2DM), which results from the deficient action of insulin, triggering the aberrant synthesis of hepatic glucose, secretion deviations, and insulin resistance in target tissues (liver, muscle, and adipose tissue), with consequent progressive deterioration of pancreatic β-cells functions [1–3]. Patients with T2DM are not insulin dependent, unlike those with T1DM, as long as lifestyle interventions and oral hypoglycemic agents are sufficient for effective glycemic control [1,3,4]. Accounting for about 90% of the worldwide cases of DM, and the sixth leading cause of disability, T2DM is clinically detected mainly by the 3 Ps: polyuria, polydipsia, and polyphagia, as well as body weight loss, distorted vision, and fatigue [1,3–7]. The disease can be attributed, on the one hand, to behavioral/environmental factors, and, on the other hand, to not fully understood genetic factors with an influence on β-cells [2,7–9]. Nevertheless, the main risk factors for the development of T2DM are oxidative stress, lack of exercise, obesity, and unhealthy diet [2,9]. Inadequate glycemic control can lead to an array of microvascular (e.g., retinopathy, nephropathy, neuropathy) and macrovascular (e.g., cardiovascular diseases such as stroke and heart attack) complications [10]. Thus, it is fundamental to develop effective strategies to restore and maintain blood glucose homeostasis. The aim of this review is to summarize some of the natural therapeutic strategies for prevention and control of T2DM, with a special emphasis on natural compounds that present pharmacological inhibitory activity against dipeptidyl peptidase-4 (DPP4), alpha-amylase, alpha-glucosidase, lipase, and protein...
tyrosine phosphatase 1B (PTP1B). These natural inhibitors include several classes of compounds such as bromophenols, phlorotannins, sterols, terpenes, stilbenoids, flavonoids, furans, catechols, and fungal metabolites, among others. The structures of some of the natural compounds mentioned across this review are represented in Figure 1.

Figure 1. Examples of chemical structures of some of the natural compounds with inhibitory activity against target enzymes in the prevention and control of T2DM. (a) theaflavin-3-gallate; (b) fucofuroeckol A; (c) triterpene oleanolic acid; (d) panclicins A; (e) percyquinnin; (f) mulberrofurans J; (g) isoderrone; (h) 3-bromo-4,5-Bis-(2,3-dibromo-4,5-dihydroxybenzyl) pyrocatechol; (i) resveratrol; (j) flavone; (k) kaempferol diglycoside.
2. Conservative Treatment

The treatment of T2DM safeguards patient-centered therapeutic individualization and is initiated by the alteration of the individual lifestyle, counterworking sedentarism, and obesity through the increase of physical activity and adoption of a balanced diet [11]. However, with progressive decline of pancreatic β-cells function, medication is required generally for extended periods of time [1,11–13]. The pharmacologic therapies are mainly based on increasing insulin availability either by direct administration of insulin or via agents promoting insulin secretion, improving insulin sensitivity, delaying gastrointestinal absorption of carbohydrates, and/or increasing glucose excretion [14]. The administration of insulin allows glycemic control, but is related to weight gain due to an increase in body fat mass, especially abdominal obesity, with consequent increase in insulin resistance, as well as episodes of hypoglycemia when the treatment is not performed properly [14].

Lifestyle Interventions: Diet and Physical Activity

Diet influences body weight, glucose, and insulin homeostasis being recognized as a risk factor for the development of T2DM [15,16]. In fact, there are several studies that verify the capacity of prevention and control of metabolic diseases by the food or by specific substances in the diet [16]. There is unanimity on the importance of body weight control, reduction of energy intake coupled with exercise, and healthy diet with low intake of processed foods (rich on refined sugars and flour) and high consumption of whole grains, fiber, polyunsaturated fatty acids, fruits, vegetables, and low-fat dairy products for the control and prevention of T2DM [2,9,16].

Processed red meat belongs to the group of foods to be avoided by the patient with T2DM, although the effect of unprocessed red meat on the pathology is not fully known [16]. The group of forbidden foods for those with T2DM also includes refined grains and sugars (high glycemic index). Preference should be given to the consumption of whole grains (low glycemic index), and, above all, fiber, with a higher consumption being recommended for T2DM patients (50 g per day) than for healthy individuals (30 g per day) [1,16]. Dietary fiber derives from plants and is not hydrolyzable by human digestive enzymes, but is digested by intestinal microflora. Dietary fibers are divided into soluble (e.g., β-glucans, pectins and some hemicelluloses) and insoluble (e.g., cellulose, some hemicelluloses and lignin) [17]. With the exception of lignin, the set of soluble and insoluble fiber, it is called non-starch polysaccharides (NSPs) [17]. When NSPs are ingested and mixed with water, they form a dispersion with an increase in the viscosity of the bolus, reducing the diffusion of digestive enzymes and promoting the sense of satiety, resulting in the fight against obesity, as well as prevention and control of T2DM [12].

On the other hand, there are foods and eating habits whose effect on T2DM remains a case study. Low-calorie and low-carbohydrate diets have beneficial effects on T2DM control, but there is no consensus for the optimal calorie intake of macronutrients in both diets [16]. According to several studies, fish consumption and the risk of developing T2DM is considered positive, inverse, or absent depending on geographical location and other factors that influence the type of fish consumed, preparation/confection methods, and contaminants (e.g., methylmercury) [16]. Nevertheless, the consumption of fish oil is recommended for a positive effect on lipoproteins and prevention of cardiac coronary diseases, being a subject of debate the discouragement the supplementation of ω-3 in diabetics [16]. Dairy consumption is recommended in T2DM prevention, especially fermented as yogurt, although the promotion of low-fat dairy products in this population is debatable [16]. Tropical and plant oils are also subjects of study in T2DM prevention and control, with evidence supporting the benefit of olive oil as part of the Mediterranean diet [16].

Regardless of the effects on body weight, physical inactivity is identified as an independent risk factor for T2DM that can be reduced by 20–60% with regular physical activity in a dose-response manner [8]. Glucose is transported by proteins called GLUT (Glucose Transporter), with GLUT4 being the predominant isoform in muscle, modulated by insulin and muscle contractions [18]. Insulin activates the intracellular transport of GLUT4 to the cell membrane through a complex signaling
sequence, which is usually compromised in individuals with T2DM, but is stimulated during aerobic or anaerobic exercise [18]. Exercise allows for the increase of GLUT4 by muscle contractions and increased glucose uptake, which is corroborated with the normal values of glucose absorption in patients with T2DM submitted to exercise protocols [18]. Glycogen is the first source of energy for exercise through glycogenolysis, resorting to plasma glucose absorption and a release of free fatty acids when the first source of energy runs out [18]. In long-term activities, glycemic control is achieved by the use of intramuscular lipid reserves [18]. In healthy subjects during moderate/intense exercise, increased peripheral glucose uptake is accompanied by increased hepatic glucose output, allowing for the maintenance of plasma glucose values, except during prolonged exercise [18]. In subjects with T2DM, during moderate exercise, glucose uptake by muscles increases more strongly than their production, leading to a decline in plasma glucose levels [18]. However, the risk of hypoglycemia reduces in non-medicated individuals with insulin or their secretagogues, due to the decrease in plasma insulin levels, even in prolonged exercise [18]. The action of aerobic exercise on insulin effect varies with duration, intensity and subsequent diet, where a single session increases the action and glucose tolerance between 24 h and less than 72 h [18]. However, brief and intense aerobic exercise increases catecholamine plasma levels, causing an increase in glucose production, which can result in hyperglycemia for 1 h to 2 h since levels do not return to normal immediately after the activity ends [18].

3. Novel Therapeutic Targets for Naturally-Occurring Compounds

3.1. Adiponectin

Adiponectin (Acrp30, AdipoQ, GBP-28, or apM1) is an endocrine factor, mainly secreted by the adipose tissue, but also by skeletal and cardiac myocytes and endothelial cells, with direct actions in the liver, skeletal muscle, and vasculature [19]. It exists in the circulation as varying molecular weight forms produced by multimerization, where the high-molecular weight complexes have apparent predominant action on metabolic tissues [19]. Adiponectin administration in human and rodents has insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects with possible decreases of body weight [19]. In fact, low plasma adiponectin concentrations are associated with obesity and T2DM regardless of ethnic groups, where hypoadiponectinemia is more closely related to the degree of insulin resistance and hyperinsulinemia than the degree of adiposity and glucose intolerance [20]. As a result of the importance of adiponectin levels in the pathology, studies have been conducted aiming the discovery of new natural sources which promote adiponectin release. Some of these studies are reviewed by Rios and colleagues, reporting different natural products for the treatment of T2DM from medicinal plants such as Ipomoea batatas, Aronia melanocarpa, and Salacia reticulate, as well as from mushroom Agaricus blazei [21].

3.2. Lipase Inhibition

Fat digestion involves gastrointestinal enzymes like pre-duodenal lipases (lingual and gastric lipases), pancreatic lipase, cholesterol-ester lipase, and bile-salt stimulated lipase [22]. Triglycerides are the most dietary fat ingested (90–95%). Their hydrolysis starts in the mouth, followed by acid stable gastric lipase in the stomach and synergistic action of gastric and colipase-dependent pancreatic lipase in duodenum [22]. As a result, monoglycerides and free fatty acids are formed, the latter being absorbed by enterocytes to synthetize new triglyceride molecules, which are transported by lipoproteins (chylomicrons) to different organs after a meal [22]. Pancreatic lipase is responsible for the hydrolysis of 50–70% of total dietary fats, highlighting it as the main lipid digesting enzyme [22,23].

3.2.1. Pharmacological Approach

The inhibition of lipase leads to restored insulin production from β-cells protecting pancreas through decrease of lipid absorption. Orlistat is the most prescribed synthetic drug for the pathology,
but with several side effects reported including steatorrhea, bloating, oily spotting, fecal urgency, fecal incontinence, and hepatic adverse effects [22,24,25]. Additionally, the inhibition of fat absorption results in the need of vitamin supplementation because of the deficiency of fat-soluble vitamins in patients undergoing orlistat therapy [22].

### 3.2.2. Naturally-Occurring Lipase Inhibitors

Considering the numerous side effects related to the use synthetic lipase inhibitors, interest in the search for new natural inhibitors against pancreatic lipase is growing. Some of them are summarized in Table 1 and described below.

#### Table 1. Natural lipase inhibitors.

| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| 5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone | Methanol extract of Dendobium formosum | IC₅₀ 69.45 ± 10.14 µM | [24] |
| Ethanol extracts of leaf essential oil of Juniperus phonicea | | IC₅₀ 60.22 µg/mL | [25] |
| Ethanolic extracts of Chrysophyllum cainito | | 74.91% inhibition and 92.11% for bioactive compounds concentrated in hexane | [26] |
| Ethanol extracts of fermented Camellia japonica | | IC₅₀ 0.308 mg/mL | [27] |
| Ethanol extracts of Camelia sinensis | | IC₅₀ 0.5 mg/mL | [28] |
| (-)-Epigallocatechin-3-gallate | Green Tea Camelia sinensis | IC₅₀ 7.5 µmol/L | |
| Theaflavin-3,3′-digallate | Black Tea Camelia sinensis | IC₅₀ 1.9 µmol/L | |
| Theaflavin-3′-gallate | Black Tea Camelia sinensis | IC₅₀ 4.2 µmol/L | |
| Theaflavin-3-gallate (Figure 1a) | Black Tea Camelia sinensis | IC₅₀ 3 µmol/L | |
| Theaflavin | Black Tea Camelia sinensis | IC₅₀ >10 µmol/L | |
| (-)-epigallocatechin-3-O-gallate | Oolong tea Camelia sinensis | IC₅₀ 54.97 ± 1.32 µM | |
| (-)-gallocatechin-3-O-gallate | Oolong tea Camelia sinensis | IC₅₀ 54.68 ± 2.23 µM | |
| (-)-epicatechin-3-O-gallate | Oolong tea Camelia sinensis | IC₅₀ 38.22 ± 0.89 µM | |
| - | | EC₅₀ 242 mM | |
| - | | EC₅₀ 0.895 mM | |
| - | | EC₅₀ 0.958 mM | |
| - | | EC₅₀ 0.885 mM | |
| - | | EC₅₀ 388 mM | |
| - | | IC₅₀ 0.8 mg/mL | |
| - | | IC₅₀ 0.8 mg/mL | |
| - | | IC₅₀ 1.2 mg/mL | |
| - | | IC₅₀ 1.2 mg/mL | |
| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| -        | Crude extract of *Oxalis cordata* |        | IC50 0.84 mg/mL | [32] |
| -        | Ethyl acetate extract of *Oxalis cordata* |        | IC50 0.88 mg/mL | |
| -        | Aqueous fraction of *Oxalis cordata* |        | IC50 0.63 mg/mL | |
| Phenolic compounds | Methanol extracts of *Eucalyptus globulus* |        | 78.92% inhibition against lipase from *Aspergillus niger* and 82.65% against lipase from olive | [33] |
| Phenolic compounds | Methanol extracts of *Mentha viridis* |        | 72.75% inhibition against lipase from *Aspergillus niger* and 75.75% against lipase from olive | |
| -        | Methanol extract of *Hibiscus sabdariffa* L. |        | IC50 35.8 ± 0.8 µg/mL | [34] |
| -        | Methanol extract of *Tamarindus indica* L. |        | IC50 152 ± 7 µg/mL | |
| -        | Aqueous extracts of *Xylopia aethiopica* |        | 92.25% inhibition | [35] |
| -        | Aqueous extracts of *Scordophloeus zenkeri* |        | 56.99% inhibition | |
| Hexadecanoic acid, methyl hexadecanoate, isopropyl palmitate, methyl 9,12-octadecadienate and methyl 9,12,15-octadecatrienoate | Chloroform fractions of *Lagenaria siceraria* |        | IC50 157.59 µg/mL | [36] |
| Furoic acid | Compounds derived from the oxidation of vitamin C |        | IC50 2.12 ± 0.04 mM | [37] |
| Oxalic acid | - | | IC50 15.05 ± 0.78 mM | |
| Polyphenols | Polyphenol rich extracts of *Phaseolus vulgaris* | oil-based turbidimetric assay | IC50 200 µg gallic acid equivalents per assay | [39] |
| - | Polyphenol rich extracts of *Ascophyllum nodosum* | - | IC50 60 µg gallic acid equivalents per assay | |
| (S)-malic acid | Ethanol and methanol extracts of *Lovi* from *Flacourtia inermis* | - | IC50 from 1290 to 2096 ppm | [40] |
| Catechin-like flavan-3-ols | *Acacia mearnsii* | - | IC50 0.95 mg/mL | [41] |
| 1,4,8-trihydroxynaphthalene-1-O-β-D [6″-O-(3″,4″,5″-trihydroxybenzoyl)] glucopyranoside | Water extract of *Juglans mandshurica* | - | IC50 2.3 mg/mL | [42] |
| Epigallocatechin gallate and revesterol | Aqueous extract of *Psidium guajava* (Pedro Sato cultivar) | In vitro | Before exposure to gastric fluid 36.45 ± 0.68 inhibited enzyme unit in µmol·min⁻¹·g⁻¹ and after exposure 43.33 ± 1.80 inhibited enzyme unit in µmol·min⁻¹·g⁻¹ | [43] |
| - | *Phagnalon lowei* | - | IC50 3.05 ± 0.07 mg/mL | [44] |
| - | Ethyl acetate extracts pits from Tunisian date palm variety Kentichi | - | IC50 5.4 ± 0.6 µg/mL | [45] |
| - | Methanol extracts pits from Tunisian date palm variety Kentichi | - | IC50 1.21 ± 0.23 µg/mL | |
| 3-O-trans-p-coumaroyl actinidic acid | Roots of *Actinidia arguta* | - | IC50 14.95 µM | [46] |
Table 1. Cont.

| Compound          | Source                          | Method                  | Results                                      | Reference |
|-------------------|---------------------------------|-------------------------|----------------------------------------------|-----------|
| Baicalin          | *Scutellaria baicalensis*       | In vitro                | IC₅₀ 293.22 ± 12.67 µM                        | [47]      |
| Wogonin           | *Scutellaria baicalensis*       | IC₅₀ 135.71 ± 9.21 µM   | IC₅₀ 56.07 ± 4.90 µM                        |           |
| Oroxynin A        | *Scutellaria baicalensis*       | From 35.2 ± 0.2% to 45.5 ± 1.2%, samples treated with pronase and from 86.2 ± 0.3% to 94.3 ± 1.5% viscozyme | [48]      |
| Polyphenols       | Winemaking generates by-products | IC₅₀ 8.6 ± 1.1mg/mL     | 92% inhibition                               | [49]      |
| Wogonin           | *Scutellaria baicalensis*       | IC₅₀ 153.71 ± 9.21 µM   | IC₅₀ 135.71 ± 9.21 µM                        |           |
| Oroxynin A        | *Scutellaria baicalensis*       | IC₅₀ 56.07 ± 4.90 µM   | IC₅₀ 56.07 ± 4.90 µM                        |           |
| Polyphenols       | Winemaking generates by-products | IC₅₀ 8.6 ± 1.1mg/mL     | 92% inhibition                               | [49]      |
| Carnosic acid     | Methanol extract of *Salvia officinalis* | IC₅₀ 12 µg/mL at 36 µM | In vitro                                     |           |
| Carnosol          | Methanol extract of *Salvia officinalis* | IC₅₀ 4.4 µg/mL         | IC₅₀ 4.4 µg/mL                               |           |
| 7-methoxyrosmanol| Methanol extract of *Salvia officinalis* | IC₅₀ 35 µg/mL         | IC₅₀ 35 µg/mL                               |           |
| Triterpene oleanolic acid (Figure 1c) | Methanol extract of *Salvia officinalis* | IC₅₀ 28.63 µmol        | IC₅₀ 0.14 µM                                 | [54]      |
| Crocin            | *Gardenia jasminoides*          | IC₅₀ 83 µg/mL           | IC₅₀ 83 µg/mL                               |           |
| Lipstatin         | *Streptomyces toxytricini*      | IC₅₀ 28.63 µmol         | IC₅₀ 0.14 µM                                 |           |
| Pancilcos A (Figure 1d) | *Streptomyces sp.*               | IC₅₀ 2.9 µM            | IC₅₀ 2.9 µM                                 |           |
| Pancilcos B       | *Streptomyces sp.*              | IC₅₀ 2.6 µM            | IC₅₀ 2.6 µM                                 |           |
| Pancilcos C       | *Streptomyces sp.*              | IC₅₀ 0.62 µM           | IC₅₀ 0.62 µM                                 |           |
| Pancilcos D       | *Streptomyces sp.*              | IC₅₀ 0.66 µM           | IC₅₀ 0.66 µM                                 |           |
| Pancilcos E       | *Streptomyces sp.*              | IC₅₀ 0.89 µM           | IC₅₀ 0.89 µM                                 |           |
| Valilactone       | *Streptomyces alboulongus*      | IC₅₀ 0.14 nm           | IC₅₀ 0.14 nm                                 |           |
| Ebelactones A     | *Streptomyces aburavensis*      | IC₅₀ 3 nm/mL           | IC₅₀ 3 nm/mL                                 |           |
| Ebelactones B     | *Streptomyces aburavensis*      | IC₅₀ 0.8 nm/mL         | IC₅₀ 0.8 nm/mL                               |           |
| Esteratin         | *Streptomyces lavendulae*       | IC₅₀ 0.2 ng/mL         | IC₅₀ 0.2 ng/mL                               |           |
| Vibralactone      | *Boreostereum virans*           | IC₅₀ 0.14 µg/mL        | IC₅₀ 0.14 µg/mL                              |           |
| Percyquinun (Figure 1e) | *Basidiomycete sterren complicatum* | IC₅₀ 2 µM              | IC₅₀ 2 µM                                   |           |

Plants

Roh & Jung reported inhibitory activity of porcine pancreatic lipase in crude extracts of *Rubi Fructus* (32.5%), *Corni Fructus* (34.8%), *Salicis Radicis et Cortex* (38%) and *Geranium nepalense* (31.4%) at 100 µg/mL [23].

5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone isolated from a methanol extract of the whole plant of *Dendobium formosum* at 50 µg/mL is related with non-competitive inhibition of alpha-glucosidase (96%) and pancreatic lipase (83%), reveling IC₅₀ (half maximal inhibitory concentration) values of 126.88 ± 0.66 µM, and 69.45 ± 10.14 µM, respectively [24].

Hexane and methanol extracts of leaf essential oil of the Tunisian traditional medicine *Juniperus phonicea* also showed an inhibitory effect against alpha-amyrase (IC₅₀ = 30.15 µg/mL) and lipase...
(IC$_{50}$ = 60.22 µg/mL), respectively, where the inhibitory capacity against the latter enzyme was coincident with their total phenolic compounds [25]. Ethanolic extracts of star apple Chrysophyllum cainito appears to present an inhibitory effect against pancreatic lipase (74.91%), and the concentration of its bioactive compounds in hexane showed 92.11% inhibition [26]. In fact, there are many studies involving the antipancreatic lipase properties of plants, including methanol extracts of fermented Camellia japonica (IC$_{50}$ = 0.308 mg/mL) [27]; ethanol extracts of Camellia sinensis (IC$_{50}$ = 0.5 mg/mL), Ceratonia siliqua (IC$_{50}$ = 0.8 mg/mL), Curcuma longa (IC$_{50}$ = 0.8 mg/mL), Sarcopterium spinosum (IC$_{50}$ = 1.2 mg/mL), and Mentha spicata (IC$_{50}$ = 1.2 mg/mL) [28]; crude extract (IC$_{50}$ = 0.84 mg/mL), ethyl acetate extract (IC$_{50}$ = 0.88 mg/mL) and aqueous fraction (IC$_{50}$ = 0.63 mg/mL) of Oxalis cordata [32]. Eucalyptus globulus and Mentha viridis where evaluated for their inhibitory potential against lipase from Aspergillus niger and extracted from olive mesocarp [33]. The investigators found that methanol extracts from E. globulus and M. viridis presented greatest inhibition against lipase of Aspergillus niger (78.92 and 72.75%, respectively) and against lipase of olive (82.65 and 75.75%, respectively), where phenolic compounds might be a major contributor for the lipases inhibition [33]. Black tea (Camelidia sinensis) theaflavins coupled with thearubigins are characteristic polyphenols in black tea, resulting from the oxidation of tea leaves during fermentation process [29]. (−)-Epigallocatechin-3-gallate is the major polyphenol in green tea and inhibit lipase in a non-competitive way, with IC$_{50}$ of 7.5 µmol/L [29]. Theaflavin-3,3′-digallate, theaflavin-3′-gallate, theaflavin-3-gallate and theaflavin inhibited pancreatic lipase with IC$_{50}$ of 1.9; 4.2; 3 and >10 µmol/L, respectively, where the presence and location of the galloyl ester moiety were essential for inhibitory potency [29]. Oolong tea is a semi-fermented tea which presents inhibitory activity against lipase, because of its polyphenolic content, namely (−)-epigallocatechin-3-O-gallate (IC$_{50}$ = 54.97 ± 1.32 µM), (−)-gallocatechin-3-O-gallate (IC$_{50}$ = 54.68 ± 2.23 µM) and (−)-epicatechin-3-O-gallate (IC$_{50}$ = 38.22 ± 0.89 µM) [30]. A methanol extract of Hibiscus sabdariffa (Malvaceae) also presented inhibitory effect against pancreatic lipase (IC$_{50}$ = 35.8 ± 0.8 µg/mL) and alpha-amylase (IC$_{50}$ = 29.3 ± 0.5 µg/mL), as well as the methanol extract of the leguminous Tamarindus indica (IC$_{50}$ = 152 ± 7 µg/mL) against lipase and aqueous extract against alpha-amylase (IC$_{50}$ = 139.4 ± 9 µg/mL) [34]. Commonly used Cameroonian spices where investigated for their in-vitro anti-amylase and anti-lipase activity [35]. This study revealed that aqueous extracts of Aframomum danielli, Hypodapnis zenkeri, Echinops giganteus, Aframomum citrus, Xylopia aethiopica had more than 75% inhibitory activity against pancreatic amylase, and Xylopia aethiopica (92.25%) and Scorodophloeus zenkeri (56.39%) were most effective against pancreatic lipase [35]. Masqood and colleagues evaluate the inhibitory activity of different extraction conditions of Lagenaria siceraria, revealing that chloroform fractions showed maximal inhibitory effect with IC$_{50}$ value of 157.59 µg/mL [36]. Additionally, the gas chromatography-mass spectrometry (GC/MS) analysis of the most active chloroform fractions showed the presence of hexadecanoic acid, methyl hexadecanoate, isopropryl palmitate, methyl 9,12-octadecadienate, and methyl 9,12,15-octadecatrienate [36].

Oxalic and furoic acid, which are compounds derived from the oxidation of vitamin C to dehydroascorbic acid, were investigated for their inhibitory activity against pancreatic lipase [37]. In this study, furoic acid and oxalic acid revealed IC$_{50}$ values of 2.12 ± 0.04 and 15.05 ± 0.78 mM, respectively, where the ultraviolet (UV) wavelength scanning and fluorescence quenching experiments proved that furoic acid inhibition was stronger than that of the other compound [37]. Both acids presented reversible inhibition with non-competitive and competitive action by furoic and oxalic acid, respectively [37]. Other compounds evaluated for their potential as lipase inhibitors include terpenes, like carnosic acid isolated from methanol extract of Salvia officinalis at 36 µM (IC$_{50}$ = 12 µg/mL) and bioactive-guided fractionation of this plant with isolation of carnosol, roylenoic acid, 7-methoxyrosmanol, and triterpene oleanolic acid with IC$_{50}$ values of 4.4; 35; 32; and 83 µg/mL, respectively [34]. Other terpenes include crocin from Gardenia jasminoids with an IC$_{50}$ value of 28.63 µmol [54].
Polyphenolic Compounds—Fruits, Vegetables and Plants

The beneficial effect of polyphenols and their subgroups on lipid metabolism is extensively reported on literature. Flavonoids are the most common group of polyphenolic compounds in the human diet and are found ubiquitously in plants, mainly on leaves or shells, with the function of protecting them from harmful external influences [55]. Flavonoids can be classified, based on the degree of the oxidation of the C-ring, the hydroxylation pattern of the ring structure and the substitution of the C3-position, into: chalcones, dihydrochalcones, aurones, flavones, flavonols, dihydroflavonoles, flavanones, flavanols, anthocyanidins, leucoanthocyanidins, proanthocyanidins, bioflavonoids, and isoflavonoids [55]. On the other hand, phenolic acids occur as free fatty acids, esters, glycosides, or bound complexes, with antioxidant, anticarcinogenic, and antimicrobial activity, where hydroxycinnamic acids are phenolic compounds with major importance for secondary metabolism in plants occurring in fruits (apples, blueberries), vegetables (spinach, lettuce, potatoes), coffee, and cereals [55]. By-products rich in polyphenols from winemaking, were treated with pronase and viscozyme to improve the solubility of phenolics by Camargo and colleagues [48]. The study revealed that the inhibition of soluble phenolics against alpha-glucosidase and lipase increased from 75.6% ± 2.5% to 93.7 ± 0.5% and from 35.2 ± 0.2% to 45.5 ± 1.2%, respectively, in samples treated with pronase and from 84.5 ± 0.5% to 96.5 ± 2.9% and from 86.2 ± 0.3% to 94.3 ± 1.5%, respectively, with viscozyme [48]. Polyphenol-rich extracts of six common bean cultivars (Phaseolus vulgaris) showed inhibitory activity against alpha-amylase (IC$_{50}$ values ranged from 69 ± 1.9 to 126 ± 3.2 µg/mL and from 107.01 ± 4.5 to 184.20 ± 5.7 µg/mL before and after cooking), alpha-glucosidase (IC$_{50}$ values ranged from 39.3 ± 4.4 to 74.13 ± 6.9 µg/mL and from 51 ± 7.7 to 122.1 ± 5.2 µg/mL before and after cooking) and pancreatic lipase (IC$_{50}$ values ranged from 63.11 ± 7.5 to 103.2 ± 5.9 µg/mL and from 92 ± 6.3 to 128.5 ± 7.4 µg/mL before and after cooking) [38]. Ethanol and methanol extracts from Loquii (Botoko plum) from Flacourtia inermis, found in Sri Lanka exhibited inhibitory activity against alpha-glucosidase (IC$_{50}$ from 549 to 710 ppm), alpha-amylase (IC$_{50}$ from 1021 to 1949 ppm) and lipase (IC$_{50}$ from 1290 to 2096 ppm), where (S)-malic acid was characterized as the active principle for this inhibition effect [40]. Additionally, this fruit has great polyphenol (1.28 g gallic acid equivalents per 100 g of fresh fruit) and anthocyanin (108 mg cyaniding-3-glucoside equivalents per 100 g fresh fruit) content [40]. Acacia polyphenol extracted from the bark of the black wattle tree (Acacia mearnsii) was tested for its in-vitro inhibitory activity against lipase and glucosidase, as well as its effects on absorption of orally administered olive oil, glucose, sucrose, and starch solution in ICR mice [41]. The results showed that acacia polyphenol inhibited the activity of lipase (IC$_{50}$ = 0.95 mg/mL), maltase (IC$_{50}$ = 0.22 mg/mL) and sucrase (IC$_{50}$ = 0.60 mg/mL) and inhibited the rise plasma triglyceride concentration after olive oil loading, rise in plasma glucose concentration after maltose (more potent), glucose and sucrose loading [41]. Water extract of Juglans mandshurica strongly inhibited pancreatic lipase in-vitro (IC$_{50}$ = 2.3 mg/mL for 50% of inhibition) with further evaluation of this activity in isolated compounds revealing potent inhibitory effect of 1,4,8-trihydroxynaphthalene-1-O-β-D [6’-O-(3′,4′,5′-tri-hydroxybenzoyl)] glucopyranoside (88% at 1 mM) [42]. Simão and colleagues tested the inhibitory potential of an aqueous extract from the leaves of three cultivars of Psidium guajava (guava) on α-amylase, α-glucosidase, lipase and trypsin enzymes. These studies were done in the presence or absence of simulated gastric fluid and the content of phenolic compounds was determined [43]. The study revealed that all cultivars showed the same phenolic composition but in different proportions, where catechin was the major compound in Paluma cultivar, epigallocatechin gallate, and revesterol in Pedro Sato and syringic acid, o-coumaric acid, and quercetin for Sécculo XXI [43]. The enzyme inhibition occurred in major proportion for Sécculo XXI cultivar against alpha-amylase before the exposure to gastric fluid (14410.60 ± 38 inhibited enzyme unit in µmol-min$^{-1}$g$^{-1}$ and Paluma against alpha-glucosidase before (28.82 ± 0.02 inhibited enzyme unit in µmol-min$^{-1}$g$^{-1}$) and after exposure (2.59 ± 0.06 inhibited enzyme unit in µmol-min$^{-1}$g$^{-1}$) [43]. Pedro Sato revealed the highest inhibitory effect against lipase before (36.45 ± 0.68 inhibited enzyme unit in µmol-min$^{-1}$g$^{-1}$) and after exposure (43.33 ± 1.80 inhibited enzyme unit in µmol-min$^{-1}$g$^{-1}$) [43]. The three cultivars presented an inhibitory effect against trypsin activity before exposure, with significant
Saponins are composed by sugars attached to a steroid or triterpene, which are primary constituents of the roots and rhizomes of various plants, being responsible for a diversity of biological effects [54]. These plants with potential against lipase include: Platycodon grandiflorum (isolated platycodin D from radix), Scabiosa tschiliensis (prosapogenin 1b at 0.12 mg/mL), Accanthopanax sessilis (sessilisoxide and chisanoiside IC\textsubscript{50} values of 0.36 and 0.75 mg/mL, respectively), Panax japonicus, Dioscorea nipponica (dioscin IC\textsubscript{50} of 20 µg/mL), and Cylcocarea paliurus (extract present IC\textsubscript{50} of 9.1 mg/mL) [54]. Tea saponin, oleanolic acid, betulin, ginsenoside Ro, and ginsenoside Rd were investigated in-vitro through comprehensive evaluation of pancreatic lipase activity [31]. Tea saponin inhibit lipase in a competitive way, while the other triterpenoid saponins act non-competitively, where the inhibitory efficiency towards lipase was different in each saponin possibly due to the different structures of this compounds [31]. The EC\textsubscript{50} value was 0.885 mM for Ro; 0.895 mM oleanolic acid; 0.958 mM for botulin; 242 mM for tea saponin; and 388 mM for Rd [31]. In another study with plant species of Madeira Argyranthemum pinnatifidum leaves and flowers exhibit inhibition activity against yeast alpha-glucosidase (IC\textsubscript{50} = 0.57 ± 0.03 mg/mL and 0.81 ± 0.02 mg/mL, respectively) and alpha-amylase (IC\textsubscript{50} = 1.55 ± 0.04 mg/mL and 2.18 ± 0.05 mg/mL, respectively) [44]. Alpha-amylase was also inhibited by Artemisia argentea leaves and flowers (IC\textsubscript{50} = 1.81 ± 0.03 mg/mL and 2.48 ± 0.04 mg/mL, respectively), Helichrysum devium (IC\textsubscript{50} = 1.85 ± 0.06 mg/mL and 2.39 ± 0.03 mg/mL, respectively), and Helichrysum melaleucum (IC\textsubscript{50} = 1.71 ± 0.02 mg/mL and 2.15 ± 0.05 mg/mL, respectively) [44]. Lipase was inhibited by Phagnalon lowei leaves (IC\textsubscript{50} = 3.05 ± 0.07 mg/mL) [44]. Pits from Tunisian date palm variety Kentichi, exhibit inhibitory activity against α-amylase and lipase with ethyl acetate (IC\textsubscript{50} = 25.4 ± 0.6 µg/mL and IC\textsubscript{50} = 5.4 ± 0.6 µg/mL, respectively) and methanol (IC\textsubscript{50} = 0.072 ± 0.003 µg/mL and IC\textsubscript{50} = 1.21 ± 0.23 µg/mL, respectively) extracts[45]. Other examples of plants with an inhibitory effect against lipase include 3-O-trans-p-coumaroyl actinidic acid isolated from roots of Actinidia arguta (IC\textsubscript{50} = 14.95 µM) [46]; and baicalin, wogonin, and oroxylin A flavonoids from Scutellaria baicalensis (IC\textsubscript{50} of 229.22 ± 12.67, 153.71 ± 9.21 and 56.07 ± 4.90 µM, respectively) [47].

Condensed tannins called proanthocyanidins are found in the insoluble fraction of plant-derived foodstuffs (e.g., grape seed and skin, red wine, apples), where type-B are the more abundant and type-A are abundant in vegetables like peanut skin, avocados, and cranberries [49]. When the degree of polymerization of proanthocyanidins is >3, they are poorly absorbed in the intestine, reaching the colon as substrate for specific bacteria of the resident microbiota, contributing to the modulation of the composition of the colonic microbiota [49]. In the lumen of the small intestine, high molecular-weight condensed tannins may interfere with macronutrients, bile salts, mucosal alpha-glucosidase, and pancreatic enzymes (alpha-amylase, lipase and proteases) decreasing nutrient digestibility, being frequently considered as antinutrients [49]. In fact, grape extract exhibits inhibitory activity against lipase with an IC\textsubscript{50} value of 8.6 ± 1.1 mg/mL [49].

**Polyphenolic Compounds—Seaweed**

Seaweed are extensively studied for their health benefits; namely, inhibition of certain crucial enzymes for the control/prevention of DM. These studies include: ethanol extract of dried Kappaphycus striatus with 92% inhibition against lipase activity and 88% for fresh Eucheuma denticulatum against alpha-amylase [50]; purified active inhibitor caulerpenyne from ethyl acetate extraction of Caulerpa taxifolia competitively inhibited 50% of lipase activity using emulsified triolein and dispersed 4-methylumbelliferyl oleate as substrates at 2 mM and 13 µM, respectively [51]. Additionally, methanolic extract of brown seaweed Eisenia bicyclus revealed an inhibitory effect of pancreatic lipase, with IC\textsubscript{50} values ranging from 37.2 ± 2.3 to 12.7 ± 1 µM for fucofuroeckol A and 7-phloroeckol, respectively [52]. Brown seaweed Saccharina japonica fermented by red mold Monascus purpureus inhibited alpha-amylase (IC\textsubscript{50} = 0.98 ± 0.10 mg/mL), rat intestinal alpha-glucosidase (maltose IC\textsubscript{50} =
0.02 ± 0.07 mg/mL and sucrose IC₅₀ = 0.08 ± 0.13 mg/mL) and lipase (IC₅₀ = 4.98 ± 0.85 µg/mL) [53].

Austin and colleagues, verified that a polyphenol-rich extract from the edible seaweed *Ascophyllum nodosum* inhibited pancreatic lipase activity in an oil-based turbidimetric assay (IC₅₀ = 200 µg gallic acid equivalents per assay) as well as its purified phlorotannin-enriched fraction (IC₅₀ = 60 µg gallic acid equivalents per assay) [39].

Alginates from Algae

Alginates are dietary fibers found in the cell walls of brown seaweed and certain bacteria and comprised of mannuronic and guluronic acid. Wilcox and colleagues found that alginate inhibited pancreatic lipase by a maximum of 72.2 ± 4.1% with synthetic substrate (DGGR) and 58 ± 9.7% with olive oil as substrate, where High-G alginates from *Laminaria hyperborea* seaweed has shown the most potent inhibitory activity than High-M alginates from *Lessonia nigrescens*, revealing that the alginate structure is related to the inhibition [56].

Metabolic Products from Microorganisms

According to a review by Birari and Bhutani, metabolic products from microorganisms can also inhibit pancreatic lipase [54]. These products include: lipstatin isolated from *Streptomyces toxytricini* (IC₅₀ = 0.14 µm); panclicins from *Streptomyces* sp. (panclicins A, B, C, D, E with IC₅₀ values of 2.9; 2.6; 0.62; 0.66; 0.89 µM, respectively); valilactone from *Streptomyces albolongus* (IC₅₀ = 0.14 nm); ebe lac tones A and B from *Streptomyces aburaviensis* (IC₅₀ of 3 and 0.8 nm/mL, respectively); esterastin from *Streptomyces lavendulae* (IC₅₀ = 0.2 ng/mL); caulerpenyne from *Caulerpa taxifolia* (IC₅₀ of 2 mM and 13 µM with emulsified triolein and dispersed 4-methyl-belliferyl oleate as substrates, respectively); vibralactone from *Boreostereum virans* (IC₅₀ = 0.14 µg/mL); and percyquinnin from *Basidiomycete stereum complicatum* (IC₅₀ = 2 µm) [54].

3.3. PTP1B Inhibition

The enzyme responsible for the reversal insulin receptor auto phosphorylation is a tyrosine phosphatase known as PTP1B (protein tyrosine phosphatase 1B), where inhibition results in a prolonged insulin signaling cascade, increasing insulin sensitivity [57]. However, low selectivity over the other protein tyrosine phosphatases, ubiquitously expressed, and poor cell permeability are two major challenges in the discovery of efficient inhibitors [58]. Nevertheless, there are potential PTP1B inhibitors from natural sources, some of these being described in Table 2.

Polyphenols mulberrofurans C, J and F from *Morus alba* showed the best inhibitory effect against PTP1B in a study by Huang and colleagues, with IC₅₀ values of 0.72 ± 0.09, 0.60 ± 0.07, and 0.57 ± 0.16 µM, respectively [59]. Caffeoylquinic acid derivate chlorogenic acid from leaves of *Artemisia princeps* is a noncompetitive inhibitor with IC₅₀ value of 11.1 µM using ursolic acid (known PTPB1 inhibitor) as positive control (IC₅₀ = 3.1 µM) [60]. Isoderrone, derrone, alpinumisoflavone, and mucusisoflavone isolated from ethanol-water extract of *Ficus racemosa* exhibit inhibitory activity against PTP1B with IC₅₀ values of 22.7 ± 1.7, 12.6 ± 1.6, 21.2 ± 3.8, and 2.5 ± 0.2 µM, respectively [61]. Ezzat and colleagues reviewed marine-derived bioactive molecules as PTP1B inhibitors where they mentioned this activity in sulfircin (sesterpene sulfate) isolated from deep-water sponge *Ircinia*, bromophenols from red algae *Rhodomela confervoides* is a noncompetitive inhibitor with IC₅₀ of 8.4 to 4.5 µM, two bromophenols from Indonesian marine sponge *Lamellodysidea herbacea* (IC₅₀ 0.9 and 1.7 µM), and others from red algae *Symphyocladia latiuscula* (IC₅₀ 3.9, 4.3 and 2.7 µM) [62]. Other compounds mentioned in this review include brominated metabolites from red algae *Laurencia similis*, polybromodiphenyl ether derivatives from marine sponge *Lamellodysidea herbacea*, eckol, and its derivatives isolated from brown algae *Ecklonia stolonifera* and *Eisenia bicyclis* [62].
| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| -        | Methanol extract from Rosemary | | IC\textsubscript{50} 40.9 ± 7.2 µM (commercial) | [57] |
| -        | Methanol extract from Mexican oregano | | IC\textsubscript{50} 37.3 ± 6.8 µM (commercial) | |
| -        | Methanol extract from Marjoram | | IC\textsubscript{50} 32.4 ± 17.5 µM (commercial) | [59] |
| Mulberrofurans C | Morus alba | | IC\textsubscript{50} 0.72 ± 0.09 µM | [60] |
| Mulberrofurans J | Morus alba | | IC\textsubscript{50} 0.60 ± 0.07 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 0.57 ± 0.16 µM | |
| Caftaric acid derivate chlorogenic acid | Leaves of Artemisia princeps | | IC\textsubscript{50} 11.1 µM | [61] |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 22.7 ± 1.7 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 12.6 ± 1.6 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 21.2 ± 3.8 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 2.5 ± 0.2 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 2.4 µM | [62] |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 1.7 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 1.5 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 1.2 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 0.8 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 0.8 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 3.4 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 4.5 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 2.4 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 2.8 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 65.3 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 69.8 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 2.7 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 0.9 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 1.7 µM | |
| Mulberrofurans F | Morus alba | | IC\textsubscript{50} 0.6 µM | |
| Compound                                                                                                                                       | Source                            | Method      | Results         | Reference |
|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-------------|-----------------|-----------|
| 3,5-Dibromo-2-(3′,5′-dibromo-2′-methoxyphenoxy) phenylbutanoate                                                                           | Lamellodysidea herbacea           | IC₅₀        | 0.7 µM          | [62]     |
| 3,5-Dibromo-2-(3′,5′-dibromo-2′-methoxyphenoxy) phenylhexanoate                                                                           | Lamellodysidea herbacea           | IC₅₀        | 0.7 µM          |          |
| 3,5-Dibromo-2-(3′,5′-dibromo-2′-methoxyphenoxy) phenyl benzoate                                                                           | Lamellodysidea herbacea           | IC₅₀        | 1 µM            |          |
| 5,5′-(3-Bromo-4,5-dihydroxy-1,2-phenylene)-Bis-(methylene))Bi-(3,4-dibromobenzene-1,2-diol)                                              | Rhodomela confervoides            | IC₅₀        | 1.7 µM          |          |
| 3,4-Dibromo-5-(2-bromo-3,4-dihydroxy-6-(ethoxymethyl)benzyl)benzene-1,2-diol                                                               | Rhodomela confervoides            | IC₅₀        | 0.84 µM         |          |
| 2-(30,50-Dibromo-20-methoxyphenoxy)-3,5-dibromophenol                                                                               | Lamellodysidea herbacea           | IC₅₀        | 0.9 µM          |          |
| 2-(30,50-Dibromo-20-methoxyphenoxy)-3,5-dibromophenol-methyl ether                                                                         | Lamellodysidea herbacea           | IC₅₀        | 1.7 µM          | [62]     |
| 2,3,6-Tribromo-4,5-dihydroxybenzyl methyl ether                                                                                           | Symphyocladia latiuscula          | IC₅₀        | 3.9 µM          |          |
| Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl) methane                                                                                           | Symphyocladia latiuscula          | IC₅₀        | 4.3 µM          |          |
| 1,2-Bis-(2,3,6-tribromo-4,5-dihydroxyphenyl)ethane                                                                                         | Symphyocladia latiuscula          | IC₅₀        | 2.7 µM          |          |
| 3′,5′,6′,6′-Tetramethoxy-2,4-dimethyldiphenyl ether                                                                                            | Laurencia similis                 | IC₅₀        | 3 µM            |          |
| 2′,5′,6′,5,6-Pentabromo-3′,4′,3,4-tetramethoxybenzo-phenone                                                                              | Laurencia similis                 | IC₅₀        | 2.7 µM          |          |
| 3′,5′,6′-Tetramethoxy-2,4-dimethyldiphenyl ether                                                                                            | Laurencia similis                 | IC₅₀        | 3 µM            |          |
| 1,2,5-Tribromo-3-bromoamino-7-bromomethylnapthalene                                                                                         | Laurencia similis                 | IC₅₀        | 102 µM          |          |
3.4. DPP4 Inhibition

3.4.1. Incretins and DPP4

Incretins are hormones produced by intestinal enteroendocrine cells on ingestion of glucose [2,11]. Incretins such as GIP (glucose-dependent insulinotropic polypeptide) and mainly GLP-1 (glucagon-like peptide-1) are responsible for the incretin effect, resulting from the observation that oral glucose is more effective in promoting insulin secretion than intravenous glucose [14]. Thus, 70% of postprandial insulin is secreted by pancreatic β-cells as a response to this incretin effect, being both this effect and physiological activity of the incretins reduced in T2DM [2,11,63]. GLP-1, in addition to insulinotropic action in response to high concentrations of glucose, allows weight loss through the mediation of satiety and reduction of gastric emptying rate, being also responsible for the suppression of glucagon secretion by pancreatic α-cells in a glucose-dependent process, allowing the cessation of hepatic glucose secretion [14,63]. When plasma glucose levels return to normal, the inhibitory effect under alpha-cells ceases, preventing hypoglycemia [63]. GIP, like GLP-1, allows for the increase of the insulin secretion and inhibition of the glucagon discharge, emphasizing this by stimulating the secretion of glucagon during hypoglycemia [63]. GLP-1 and GIP are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP4) widely distributed throughout the body [64].

3.4.2. Pharmacological Approach

Active GLP-1 has a half-life of 1–2 min and its inhibition constitute an efficient pharmacological approach for T2DM treatment [4]. In fact, a new class of drugs has emerged, which allows the stimulation of endogenous insulin secretion, preventing the rapid degradation of incretin hormones, through the inhibition of DPP4 [65]. DPP4 inhibitors, or gliptins, are effective as monotherapy and in combination therapy, allowing the reduction of HbA1c without causing hypoglycemia or weight gain [11]. Gliptins can be classified as peptidomimetics (designed to mimic the N-terminal dipeptide that is cleaved by DPP4) such as Vildagliptin and Saxagliptin, or non-peptidomimetics such as Linagliptin and Sitagliptin [66]. The most widely antihyperglycemic agent prescribed worldwide is metformin, despite its association with vitamin B12 deficiency and contraindication in patients with chronic kidney disease [4,5]. Another class of drugs based on the incretin effect refers to GLP-1 analogues, namely exenatide, which demonstrates statistically significant body weight reduction when compared to insulin/placebo [14]. Besides the existing pharmacological strategies, side effects and contraindications reveal the need for new natural therapies for inhibition for DPP4 [67]. In fact, the prolonged usage of these medications causes side effects such as pancreatitis, angioedema, infective disorders, pancreatic cancer, thyroid cancer, and severe joint pain [68], increasing interest of the scientific community for the development of natural inhibitors (Table 3).
### Table 3. Natural DPP4 inhibitors.

| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| Caseins  | Protein hydrolysates cow’s milk | In silico | Occurrence frequency 0.249 (beta-casein), 0.380 (bovine meat) and 0.305 (salmon). Gly-Ala, Gly-Pro and Pro-Gly were the most frequently occurring sequences | [69] |
| Collagens| Protein hydrolysates bovine meat and salmon | | | |
| Gly-Pro-Gly-Ala | Protein hydrolysates Atlantic salmon skin gelatin | | IC₅₀ 49.6 μM | |
| Gly-Pro-Ala-Glu | Protein hydrolysates tuna cooking juice | | IC₅₀ 78 μM | |
| Pro-Gly-Val-Gly-Gly-Pro-Leu-Gly-Pro-Ile-Gly-Pro-Cys-Tyr | | | IC₅₀ 96.4 μM | |
| Cys-Ala-Tyr-Gln-Trp-Gln-Arg-Pro-Val-Asp-Arg-Ile-Arg | Protein hydrolysates tuna cooking juice | | | |
| Pro-Ala-Cys-Gly-Phe-Tyr-Ile-Ser-Gly-Arg-Pro-Gly | | | | |
| Leu-Pro | Protein hydrolysates Japanese rice bran | | IC₅₀ 410 μM | |
| Ile-Pro | | | IC₅₀ 870 μM | |
| Met-Pro | | | IC₅₀ 880 μM | |
| Val-Pro | | | IC₅₀ 2240 μM | |
| Arg-Pro | | | IC₅₀ 2370 μM | |
| Thr-Pro | | | | |
| Leu-Pro | Protein hydrolysates Japanese rice bran | In vitro | | [66] |
| Lys-Pro | | | IC₅₀ 2370 μM | |
| His-Pro | | | IC₅₀ 2540 μM | |
| Tyr-Pro | | | IC₅₀ 2820 μM | |
| Phe-Pro | | | IC₅₀ 3170 μM | |
| Trp-Pro | | | IC₅₀ 3630 μM | |
| Pro-Pro | | | IC₅₀ 4530 μM | |
| Ser-Pro | | | IC₅₀ 5660 μM | |
| Ala-Pro | | | IC₅₀ 5980 μM | |
| Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu | Protein hydrolysates gouda cheese | | IC₅₀ 46 μM | |
| Leu-Pro-Gln-Asn-Ile-Pro-Pro-Pro | | | IC₅₀ 160 μM | |
| Pro-Gln-Asn-Ile-Pro-Pro-Leu | | | IC₅₀ 1500 μM | |
| Leu-Pro-Pro | Protein hydrolysates gouda cheese | | IC₅₀ 82 μM | |
| Val-Pro-Ile-Thr-Pro-Thr | | | IC₅₀ 130 μM | |
| Val-Pro-Ile-Thr-Pro-Leu | | | IC₅₀ 110 μM | |
| Phe-Pro-Gly-Pro-Ile-Pro-Asp | | | IC₅₀ 260 μM | |
| Pro-Gly-Pro-Ile-His-Asp-Ser | | | IC₅₀ 1000 μM | |
| Ile-Pro-Pro-Leu-The-Gln-Thr-Pro-Val | | | IC₅₀ 130 μM | |
| Val-Pro-Pro-Phe-Ile-Gln-Pro-Glu | | | IC₅₀ 2500 μM | |
| Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asp | | | IC₅₀ 670 μM | |
Table 3. Cont.

| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| Val-Ala-Gly-Thr-Trp-Tyr | Protein hydrolysates β-lactoglobulin | IC_{50} 174 µM | | |
| Ile-Pro-Ala | | IC_{50} 49 µM | | |
| Ile-Pro-Ala-Val-Phe | | IC_{50} 45 µM | | |
| Ile-Pro-Ala-Val-Phe-Lys | | IC_{50} 143 µM | | |
| Val-Leu-Val-Leu-Asp-Thr-Asp-Tyr-Lys | | IC_{50} 424 µM | | |
| Thr-Pro-Glu-Val-Asp-Asp-Glu-Ala-Leu-Glu-Lys | | IC_{50} 320 µM | | |
| Gln-Lys | Protein hydrolysates milk protein | | | |
| Gln-Lys | | IC_{50} 3216 µM | | |
| Ala-Leu | | IC_{50} 882 µM | | |
| Val-Ala | | IC_{50} 168 µM | | |
| Trp-Val | | IC_{50} 65 µM | | |
| Pro-Leu | | IC_{50} 399 µM | | |
| His-Leu | | IC_{50} 143 µM | | |
| Ser-Leu | | IC_{50} 2517 µM | | |
| Trp-Val Synthetic dipeptides | | IC_{50} 0.020 ± 0.001 mg/mL | | [70] |
| Lactoferrin hydrolysate LFH1 Milk | | IC_{50} 1.088 ± 0.106 mg/mL | | |
| Casein hydrolysate CasH2 | | IC_{50} 0.882 ± 0.057 mg/mL | | |
| Cirsimaritin, naringenin, hispidulin, eriodictyol and carnosol Methanol extract of Rosemary | | IC_{50} 28.7 ± 3.1 µM (greenhouse-grown) 6.5 ± 0.4 µM (commercial) | | [57] |
| Cirsimaritin Methanol extract of Mexican oregano | | IC_{50} 25.3 ± 0.3 µM (greenhouse-grown) 3.9 ± 0.6 µM (commercial) | | |
| Cirsimaritin Methanol extract of Marjoram Purified compounds | | IC_{50} 37.7 ± 7.9 µM (greenhouse-grown) | | |
| Naringenin | | IC_{50} 0.43 ± 0.07 µM | | |
| Hispidulin | | IC_{50} 0.49 ± 0.06 µM | | |
| Anthocyanins Blueberry-blackberry wine blends | | IC_{50} 2.5 ± 0.29 µM | | |
| Resveratrol (Figure ii) Commonly found in citrus, berry, grape and soybean | | IC_{50} 0.07 ± 0.02 to >300 µM | | [71] |
| Luteolin | | IC_{50} 0.6 ± 0.4 nM | | |
| Apigenin | | IC_{50} 0.12 ± 0.01 µM | | |
| Flavone (Figure i) | | IC_{50} 0.14 ± 0.02 µM | | |
| | | IC_{50} 0.17 ± 0.01 µM | | |
| Compound | Source | Method     | Results | Reference |
|----------|--------|------------|---------|-----------|
|          | Ethanolic precipitate of *Sargassum binderi* | In vitro | $IC_{50}$ 2.194 mg/mL | [64] |
|          | Ethanolic precipitate of *Padina sulcata* | In vitro | $IC_{50}$ 2.306 mg/mL |       |
|          | Ethanolic precipitate of *Turbinaria conoides* | In vitro | $IC_{50}$ 3.594 mg/mL |       |
|          | Methanol extract of *Sargassum wightii* | In vitro | $IC_{50}$ 38.27 µg/mL | [65] |
|          | Methanol extract of *Sargassum polycystum* | In vitro | $IC_{50}$ 36.94 µg/mL |       |
|          | Methanol extract of *Turbinaria conoides* | In vitro | $IC_{50}$ 55.2 µg/mL | [72] |
| Mangiferin | *Mangifera indica* | Rat model and ELISA | 89 ± 8% | [68] |
|          | Crude extract of marine sponge *Xetospongia muta* | In vitro | $IC_{50}$ 0.8 mg/mL (preincubation time: 10 min) Treatment with 2.5% TCA or heat (60 °C) increase 3.7 and 2.7 total inhibitory activity | [73] |
|          | Crude extracts of marine anemone *Bunodosoma granulifera* | In vitro | $IC_{50}$ 1.2 mg/mL (preincubation time: 10 min) thermal treatment destroyed inhibitory activity |       |
|          | Crude extracts of marine anemone *Bartholomea annulata* | In vitro | $IC_{50}$ 0.38 mg/mL (preincubation time: 3 min) heat or TCA treatment decreased inhibitory activity |       |
3.4.3. Naturally-Occurring DPP4 Inhibitors

Peptides

Dietary proteins have been increasingly recognized as precursors of a variety of bioactive peptides, improving various aspects of human health [74]. These bioactive peptides are present in inactive forms in food, being activated once released from the proteins by enzymatic or acid hydrolysis, microbial fermentation or processing methods, and their biological activity is determined by their native amino acid composition and sequence [74]. In-silico analyses are useful to determine the frequency of the occurrence of bioactive peptides within a dietary protein (simulation of protein hydrolysis by bioinformatic tools to calculate a number of bioactive peptides found in a given dietary protein) and binding modes by docking analysis (simulate the binding and interactions between peptides and enzymes, like DPP4, in order to evaluate the inhibitory effects of the peptides) [74]. Peptides can inhibit DPP4 with competitive (Xaa-Pro, Pro-Xaa, Xaa-Ala, and food derived peptides with proline at their P$_1$ position), non-competitive and uncompetitive (N-terminal with tryptophan amino acid) and mixed-type modes of action, exerting their effect by binding either at the active site and/or outside the catalytic center of the enzyme [75]. The DPP4 inhibitory activity of bioactive peptides has been associated with some structural characteristics like length, isoelectric point, hydrophobicity, and net charge of the peptides, being the most predominant factor the specific amino acid sequence [75]. Other characteristics associated with potent inhibitory effect are: branched-chain amino acid or an aromatic residue with a polar group in the side-chain (tryptophan) at their N-terminal and/or a proline residue, were C-terminal amino acid also influences its potency since both are involved in the interaction with DPP4 [75].

DPP4 is known to act on substrates with proline or other small-uncharged residues such as serine and alanine at their penultimate amino acid position [75]. Because of high content in proline residues, collagen from fish and mammals has also attracted notable attention as a potential source of DPP4 inhibitory peptides [66,75]. To date, protein hydrolysates and bioactive peptides from cow’s milk have been the most extensively investigated sources of DPP4 inhibitors. In fact, according to a study with in-silico approach, caseins from cow’s milk (beta-casein with an occurrence frequency value of 0.249) and collagens from bovine meat and salmon (occurrence frequency values of 0.380 and 0.305, respectively) appeared to be the richest potential sources of DPP4 inhibitors, where Gly-Ala, Gly-Pro and Pro-Gly were the most frequently occurring sequences [69]. According to a review, peptides from Atlantic salmon skin gelatin (Gly-Pro-Gly-Ala and Gly-Pro-Ala-Glu sequence), tuna cooking juice (Pro-Gly-Val-Gly-Pro-Leu-Gly-Pro-Ile-Gly-Pro-Cys-Tyr and Cys-Ala-Tyr-Gln-Trp-Gln-Arg-Pro-Val-Asp-Arg-Ile-Arg and Pro-Ala-Cys-Gly-Gly-Phe-Tyr-Ile-Ser-Gly-Arg-Pro-Gly), Japanese rice bran, Native American amaranth, and Gouda cheese also present the DPP4 inhibitory effect [66].

Peptides which were not isolated from hydrolysates but are likely to occur in the sequence of dietary proteins, were synthetically produced and studied for their effect on DPP4 activity [75]. Diprotin A (tripeptide IPI) is the most potent peptide with DPP4 inhibitory activity (IC$_{50}$ ≈ 4 µM) and can be found in the sequence of k-casein. However, not as effective as diprotin A, the peptides WR, IPIQY, and WCKDDQNH found in the sequence of lactoferrin, k-casein, and α-lactalbumin, respectively, are among the most potent food protein-derived DPP4 inhibitors reported to date [75]. However, these peptides could not be released from dietary proteins during digestion or enzymatic proteases, like those isolated and identified in hydrolysates and thus unavailable for inhibitory effect of DPP4 [75]. Nongonierma and colleagues tested a selection of synthetic dipeptides and milk protein hydrolysates for their DPP4 inhibitory properties, and their superoxide and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activities [70]. The study revealed superoxide and DPPH scavenging activity and the DDP4 inhibitory effect, by dipeptide Trp-Val (EC$_{50}$ 39.75 ± 0.01 mg/mL; EC$_{50}$ 0.07 ± 0.01 mg/mL; IC$_{50}$ 0.020 ± 0.001 mg/mL respectively) and lactoferrin hydrolysate LFH1 (EC$_{50}$ 0.10 ± 0.01 mg/mL; EC$_{50}$ 1.15 ± 0.40 mg/mL; IC$_{50}$ 1.088 ± 0.106 mg/mL). However, the dipeptide Ala-Leu had bigger
superoxide scavenging activity (EC\textsubscript{50} 1.74 ± 0.01 mg/mL) than Trp-Val, which was the dipeptide with greater DPPH scavenging activity [70]. Besides LHF1, casein hydrolysate (CasH2) also showed a potent inhibitory effect on DPP4 (IC\textsubscript{50} 0.882 ± 0.057 mg/mL) [70].

Polyphenolic Compounds: Fruits, Vegetables, and Plants

The potential of phenolic compounds in the treatment and prevention of obesity is due to their thermogenic effects, which corresponds to the ability to oxidize fat and decrease intestinal absorption of fats and carbohydrates, resulting in the inhibition of digestive enzymes with consequent weight loss [43]. Beneficial health effects of fruits and vegetables in the diet have been attributed to their high phenolic content, such as flavonoids. With the purpose of inhibit DPP4 and PTPB1, Bower and coworkers studied the ability of greenhouse-grown and commercially purchased Greek oregano (Origanum vulgare), marjoram (Origanum majorana), rosemary (Rosmarinus officinalis), and Mexican oregano (Lippia graveolens) [57]. Greenhouse herbs were richer in polyphenols than the commercial ones. Mexican oregano and marjoram were the best inhibitors of PTP1B (32.4–40.9% at 500 µM) with cirsimaritin, naringenin, hispidulin, eriodictyol, and carnosol in their composition according to LC-ESI-MS method [57]. According to computational modeling, the last three phytochemicals have the best binding affinities for DPP4, but biochemically the best inhibitors of DPP4 were cirsimaritin (IC\textsubscript{50} = 0.43 ± 0.07 µM), hispidulin (IC\textsubscript{50} = 0.49 ± 0.06 µM) and naringenin (IC\textsubscript{50} = 2.50 ± 0.29 µM), found in rosemary and Mexican oregano extracts [57]. Fan and colleagues investigated the DPP4 inhibitory effect of well-characterized anthocyanins isolated from berry wine blends, and twenty-seven other phenolic compounds commonly found in citrus, berry, grape and soybean using luminescence assay and computational modeling (for the most potent compounds) [71]. Malvidin-3-galactoside and cyaniding-3-glucoside were the main anthocyanins present in blueberry wine, while delphinidin-3-arabinoside was predominant in the blackberry wine [71]. Anthocyanins from blueberry-blackberry wine blends (IC\textsubscript{50} = 0.07 ± 0.02 to > 300 µM) and phenolics resveratrol (IC\textsubscript{50} = 0.6 ± 0.4 nM), luteolin (IC\textsubscript{50} = 0.12 ± 0.01 µM), apigenin (IC\textsubscript{50} = 0.14 ± 0.02 µM) and flavone (IC\textsubscript{50} = 0.17 ± 0.01 µM) exhibit the most strongly inhibiting activity, where phenolics present IC\textsubscript{50} values lower than diprotin A (IC\textsubscript{50} = 4.21 ± 2.01 µM) [71]. According to computational modeling, resveratrol and flavone were competitive inhibitors and luteolin and apigenin docked in a non-competitive manner [71].

Polyphenolic Compounds: Seaweed

Seaweed (also called algae) are simple unicellular (microalgae) or multicellular organisms (macroalgae), with rudimentary conductive tissues, presenting a high range of morphological and reproductive level variation that allows their division into different phyla and classes [76]. The presence of chlorophyll, production of the same carbohydrates, proteins and metabolic pathways, render algae biochemically similar to plants, differing in the absence of embryo and multicellular envelope around sporangia and gametangia in algae (except freshwater green algae, charophytes) [76]. Marine macroalgae, are rich in bioactive compounds in the form of polyphenols, carotenoids, vitamins, phycobilins, phycocyanins, and polysaccharides, known for their benefits to human health [1,76]. An in-vitro assay revealed that ethanolic precipitates of Sargassum binderi, Padina sulcata, and Turbinaria conoides had inhibitory activity against DPP4 (IC\textsubscript{50} = 2.194; 2.306 and 3.594 mg/mL, respectively) [64]. Additionally, the same study evaluated the viability of pGIP/neo STC-1 cells by measurement of cell membrane integrity by means of the Trypstat blue exclusion assay [64]. The evaluation revealed that water extracts of S. binderi, P. sulcata, and T. conoides allowed for the stimulation of GIP secretion of 5.46; 4.92 and 5 PM GIP per million cells per hour at 2.5; 10; 2.5 mg/mL, respectively [64]. Furthermore, the butanol fraction of S. binderi and P. sulcata allows for the stimulation of GIP secretion of 56.38 and 40.67 PM, respectively, GIP per million cells per hour at 5 mg/mL [64]. Another study revealed that methanol extract of brown seaweeds Sargassum wightii and Sargassum polyctenum has an inhibitory effect against DPP4 (IC\textsubscript{50} = 38.27 µg/mL and IC\textsubscript{50} = 36.94 µg/mL, respectively) and acetone extract
with moderate antioxidant activity (43% and 22%) at a concentration of 1000 µg/mL according to DPPH free radical scavenging activity method [65]. The same group of investigators found that methanol extract of brown seaweed Turbinaria conoides possesses inhibitory activity against DPP4 (55.4%, IC50 = 55.2 µg/mL) at a concentration of 80 µg/mL and significant scavenging ability on DPPH (65%) at a concentration of 1000 µg/mL of acetone extract [72].

Mangiferin is a glucosyl xanthone and is the major phytochemical in Mangifera indica (family of Anacardiaceae). It has strong antioxidant, antilipid peroxidation, immunomodulation, antidiabetic cardiotonic, hypotensive, wound healing, antithrombogenic, and antidegenerative properties [68]. Suman and colleagues studied the influence of mangiferin and synthetic drugs (metformin and vildagliptin) using two control groups of adult Wistar rats (normal control and diabetic control feed for 10 weeks with distilled water and a high-fat diet, respectively) [68]. The other subjects where fed for 10 weeks with a high-fat diet and subsequent streptozotocin (STZ)-induced T2DM (40 mg/kg) after 3 weeks, followed by the administration of metformin, vildagliptin or mangiferin from the fifth week to tenth week daily [68]. The study revealed a high DPP4 inhibitory effect of mangiferin (89 ± 8%) when compared with synthetic drugs (90 ± 7% for VIL and 84 ± 8% for sitagliptin) according to ELISA kit (Enzyme-Linked Immunosorbent Assay) [68]. Mangiferin permitted the reduction in blood glucose, HbA1c levels and MDA levels (marker of lipid peroxidation in organs like liver, heart and kidney) [68]. Additionally, this xanthone improves insulin sensitivity and C-peptide levels, showing a favorable effect on inflammatory markers hs-CRP [68]. Total cholesterol (p < 0.001), triglycerides (p < 0.001), LDL (p < 0.01), and atherogenic index (p < 0.01) were significantly reduced and HDL was increased (p < 0.01) in mangiferin and standard drugs treated groups [68]. Other marine sources with health benefits have been studied, such as sponges and anemones, where aqueous extracts of sponge Xetospongia muta and sea anemones Bunodosoma granulifera and Bartholomea annulata present inhibitory activity against DPP4 (0.82; 2.26 and 1.78 U/mg, respectively) [73].

3.5. Alpha-Amylase and/or Alpha-Glucosidase Inhibition

Pancreatic alpha-amylase allows the hydrolysis of carbohydrates through the breakdown of α-1,4-glycosidic bonds, forming linear and branched oligosaccharides, which are subsequently converted to glucose [12,13,65]. Such a conversion is catalyzed by the intestinal alpha-glucosidase, allowing its absorption into the bloodstream [12,13]. The inhibition of both enzymes, will allow to reduce the postprandial hyperglycemia by delayed digestion of carbohydrates and intestinal absorption of glucose [12,13,77].

3.5.1. Pharmacological Approach

Acarbose, miglitol and voglibose are examples of inhibitors, where the former shows an excessive inhibitory activity of pancreatic alpha-amylase with consequent abnormal bacterial fermentation of carbohydrates in the colon, resulting in side effects such as flatulence, bloating, and possible diarrhea [77]. As a result of several side effects and high costs of pharmacological control of pathology, the scientific community is constantly in the search for natural sources with inhibitory effect against alpha-amylase and alpha-glucosidase, being summarized in Tables 4 and 5, respectively, and described below.

3.5.2. Naturally-Occurring Alpha-Amylase and/or Alpha-Glucosidase Inhibitors

Peptides

Protein hydrolysate from Chinese giant salamander (Andrias davidianus) was evaluated for its potential inhibitory activity against alpha-amylase and alpha-glucosidase, with further purification and identification of antidiabetic peptides [78]. The peptides amino acid sequences were Cys-Ser-Ser-Val, Tyr-Ser-Phe-Arg, Ser-Ala-Ala-Pro, Pro-Gly-Gly-Pro, and Leu-Gly-Gly-Gly-Asn with alpha-amylase IC50 values of 13.76 × 10³, 10.82 × 10³, 4.46 × 10³, 4.23 × 10³ and 2.86 × 10³, respectively; and with alpha-glucosidase IC50 values of 206.00, 162.00, 66.90, 63.50, and 42.93 µg/mL, respectively [78]. Garza
and colleagues also reported the inhibition of alpha-amylase by valoneic acid dilactone obtained from banaba (*Lagerstroemia speciosa*), ethanol extract of chestnut astringent skin, and a purified compound isolated from white beans (*Phaseolus vulgaris*) [22].

Polyphenolic Compounds: Fruits, Vegetables, and Plants

Extracts from grape seed, green tea, and white tea were evaluated for their potential to inhibit alpha-amylase and alpha-glucosidase [79]. Grape seed extract exhibited the best inhibitory effect against alpha-amylase (IC$_{50}$ = 8.7 ± 0.8 μg/mL), followed by green tea extract (IC$_{50}$ = 34.9 ± 0.9 μg/mL), and white tea (IC$_{50}$ = 378 ± 134 μg/mL) [79]. However, green tea extract revealed the best inhibitory effect on alpha-amylase (IC$_{50}$ = 0.5 ± 0.1 μg/mL), followed by grape seed extract (IC$_{50}$ = 1.2 ± 0.2 μg/mL) and white tea extract (IC$_{50}$ = 2.5 ± 0.4 μg/mL) [79]. Another study evaluated the alpha-amylase and alpha-glucosidase inhibitory effect of acylated favonol tetracyloside (camellikaempferoside) and 14 other flavone glycosides isolated from *Camellia sinensis* [80]. The investigators found that kaempferol monoglycoside showed inhibitory activity against alpha-glucosidase (IC$_{50}$ = 40.02 ± 4.61 μM) and kaempferol diglycoside against alpha-amylase (IC$_{50}$ = 0.09 ± 0.02 μM) [80].

Aqueous extracts of *Morinda lucida* present high inhibitory effect against alpha-amylase with IC$_{50}$ = 2.36 mg/mL and α-glucosidase IC$_{50}$ = 2.00 mg/mL through a competitively and mixed noncompetitive mode of inhibition, respectively [81]. Besides these plant extracts, there are others that revealed an inhibitory activity against alpha-amylase and alpha-glucosidase, such as: *Senna surattensis* ethanolic extract (IC$_{50}$ = 123.95 μg/mL for α-amylase) [82], leaf acetone extracts of *Picralima nitida* (IC$_{50}$ = 6.50 mg/mL for α-amylase and IC$_{50}$ = 3.00 μg/mL for α-glucosidase) [83], hydroxytyrosol derivate from the phenolic compound oleroeprin present in *Olea europea* (75%, IC$_{50}$ = 150 μM at 600 μM for α-amylase) [84] and ethanol-free extract of *Abutilon indicum* (IC$_{50}$ = 191.64 mcg/mL for α-amylase and IC$_{50}$ = 207.13 mcg/mL for α-glucosidase) [85]. Aqueous methanol and n-butanol extracts of air-dried aerial parts of *Ononis angustissima* flowers, leaves and stems revealed strong inhibitory activity against alpha-glucosidase (IC$_{50}$ = 0.94 mg/mL and IC$_{50}$ = 0.99 mg/mL, respectively) [86]. However, the stronger inhibitory effect against alpha-amylase was achieved with aqueous methanol and distilled water extracts (IC$_{50}$ = 2.01 mg/mL and IC$_{50}$ = 2.52 mg/mL, respectively) [86]. Alpha-amylase and alpha-glucosidase are inhibited by the root ethanolic extract of *Cissus cornifolia*, with IC$_{50}$ value of 22.75 ± 1.23 μg/mL and 2.81 ± 0.97 μg/mL, respectively, where aqueous root extract revealed IC$_{50}$ value of 33.70 ± 3.75 μg/mL and 37.48 ± 2.35 μg/mL, respectively [87].

Ethanolic extracts (70% ethanol) of medicinal plant roselle (*Hibiscus sabdariffa*) has potent inhibitory effect against alpha-amylase and alpha-glucosidase (47.34 and 73.08%, respectively) with IC$_{50}$ values of 41.77 μg/mL for the former and 18.09 μg/mL for the latter [88]. Different commercially available chili peppers in Thailand where evaluated for their inhibitory activity against alpha-amylase and alpha-glucosidase [89]. “Sweet Pepper” and “Green Chinda” aqueous ethanolic extract (70% v/v) at 5 mg/mL exhibit the highest inhibitory activity against alpha-glucosidase (66%) and alpha-amylase (58%) [89]. On the other hand, a study revealed that purple flesh tubers extract has potent inhibitory activity against alpha-amylase, alpha-glicosidase, and aldose reductase (addressed ahead) with IC$_{50}$ values of 25, 42 and 32 μg/mL, respectively [90]. This study corroborates the opinion of some nutritionists that purple and red potato cultivars are a healthier choice for diabetic patients, rather than other types of potatoes, owing to their high levels of polyphenolic compounds with potent antioxidant activity [90].

Seaweed

Dieckol and eckol from brown alage *Eisenia bicyclis* inhibit alpha-amylase [91], while bromophenols 2,4,6-tribromophenol and 2,4-dibromophenol, from purified red algae *Grateloupia elliptica* shown inhibition against *Saccharomyces cerevisiae* alpha-glucosidase (IC$_{50}$ = 60.3 and 110.4 μM, respectively) and *Bacillus stearothermophilus* alpha-glucosidase (IC$_{50}$ = 130.3 and 230.3 μM, respectively) [92]. Furthermore, diplophosphatehydroxyxycarmalol (DPHC), a kind of phlorotanin, isolated from brow algae *Ishige okamure*, evidenced an inhibitory effect against alpha-glucosidase (IC$_{50}$ = 0.16 mM)
and alpha-amylase ($IC_{50} = 0.53$ mM) without cytotoxic effect in human umbilical vein endothelial cells in concentrations from 0.49 to 3.91 mM [93]. The inhibition of alpha-amylase also occurs in methanol (72%), ethanol (65%) and ethyl acetate (70%) extracts of green algae *Cladophora rupestris* and alpha-glucosidase in methanol (67%) and ethyl acetate (61%) extracts both inhibitions at 1000 µg/mL [94]. Phenolic extracts from red algae *Palmaria sp.* and brown algae *Alaria sp.* and *Ascophyllum sp.* (complete inhibition at 2–5 µg/mL, $IC_{50} \approx 0.1$ µg/mL) show inhibitory effect against alpha-amylase, where the last also inhibits alpha-glucosidase ($IC_{50} \approx 19$ µg/mL) [95]. Other seaweed with inhibitory activity against alpha-amylase and alpha-glucosidase include: *Ulva reticulata* and *Garcilaria edulis* [96]. In this point of view, marine resources are a valuable resource of powerful bioactive compounds for natural therapeutic strategies, especially for T2DM.
| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| Diphlorethohydroxycarmalol (DPHC) | *Isihge okamure* | *In vitro* | IC$_{50}$ 0.53 mM | [93] |
| - | *Cladophora rupestris* | | Methanol (72%), ethanol (65%) and ethyl acetate (70%) extracts | [94] |
| - | *Palmaria sp.* | | Complete inhibition at 2–5 µg/mL, IC$_{50}$ = 0.1 µg/mL | [95] |
| - | *Alaria sp.* | | Complete inhibition at 2–5 µg/mL, IC$_{50}$ = 0.1 µg/mL | [95] |
| - | *Ascophyllum sp.* | | Complete inhibition at 2–5 µg/mL, IC$_{50}$ = 0.1 µg/mL | [95] |
| - | Aqueous extract of *Ulva reticulata* | | 89.1 ± 0.96% inhibition after 8 h of extraction | [96] |
| - | Aqueous extract of *Gracilaria edulis* | | 87.86 ± 3.4% inhibition after 8 h of extraction | [96] |
| - | Grape seed extract | | IC$_{50}$ 8.7 ± 0.8 µg/mL | [79] |
| - | Green tea extract | | IC$_{50}$ 34.9 ± 0.9 µg/mL | [79] |
| - | White tea extract | | IC$_{50}$ 378 ± 134 µg/mL | [79] |
| - | Kaempferol diglycoside (Figure 1k) | *Camelia sinensis* | | IC$_{50}$ 0.09 ± 0.02 µM | [80] |
| - | Aqueous extracts of *Morinda lucida* | | IC$_{50}$ 2.30 mg/mL | [81] |
| - | Ethanolic extract from *Senna surattensi* | | IC$_{50}$ 123.95 µg/mL | [82] |
| - | Acetone extracts from *Picralima nitida* | | IC$_{50}$ 6.50 mg/mL | [81] |
| Hydroxytyrosol derivate from the phenolic compound oleuropein | *Olea europaea* | *In vitro* | IC$_{50}$ 150 µM at 600 µM | [84] |
| - | Ethanol-free extract of *Abutilon indicum* | | IC$_{50}$ 191.64 mcg/mL | [85] |
| - | Aqueous methanol extracts of *Ononis angustissima* | | IC$_{50}$ 2.01 mg/mL | [86] |
| - | Distilled water extracts of *Ononis angustissima* | | IC$_{50}$ 2.52 mg/mL | [86] |
| - | Root ethanolic extract of *Cissus cornifolia* | | IC$_{50}$ 22.75 ± 1.23 µg/mL | [87] |
| - | Aqueous root extract of *Cissus cornifolia* | | IC$_{50}$ 33.70 ± 3.75 µg/mL | [87] |
| - | Ethanolic extracts (70%) of *Hibiscus sabdariffa* | | IC$_{50}$ 41.77 µg/mL | [88] |
| - | Aqueous ethanolic extract (70% v/v) of *Capsicum annuum* | | 58% at 5 mg/mL | [89] |
| - | Purple flesh potatoes extract | | IC$_{50}$ 25 µg/mL | [90] |
| - | Cys-Ser-Ser-Val Protein hydrolysate from *Andrias davidianus* | | IC$_{50}$ 13.76 × 10$^3$ µg/mL | [78] |
| - | Tyr-Ser-Phe-Arg Protein hydrolysate from *Andrias davidianus* | | IC$_{50}$ 10.82 × 10$^3$ µg/mL | [78] |
| - | Ser-Ala-Ala-Pro Protein hydrolysate from *Andrias davidianus* | | IC$_{50}$ 4.46 × 10$^3$ µg/mL | [78] |
| - | Pro-Gly-Gly-Pro Protein hydrolysate from *Andrias davidianus* | | IC$_{50}$ 4.23 × 10$^3$ µg/mL | [78] |
| - | Leu-Gly-Gly-Gly-Asn Protein hydrolysate from *Andrias davidianus* | | IC$_{50}$ 2.86 × 10$^3$ µg/mL | [78] |
Table 4. Cont.

| Compound | Source | Method | Results | Reference |
|----------|--------|--------|---------|-----------|
| -        | Hexane extracts of leaf essential oil of *Juniperus phonicea* |        | IC$_{50}$ 30.15 µg/mL | [25] |
| -        | Methanol extract of *Hibiscus sabdariffa* |        | IC$_{50}$ 29.3 ± 0.5 µg/mL | [34] |
| -        | Aqueous extract of *Tamarindus indica* |        | IC$_{50}$ 139.4 ± 9 µg/mL | [35] |
| -        | Aqueous extract of *Aframomum danielli*, *Hydropogon zonkeri*, *Echinops giganteus*, *Aframomum citratum*, *Xylopia aethiopica* | >75% inhibition | | |
| Polyphenols | Polyphenol rich extracts of *Phaseolus vulgaris* |        | IC$_{50}$ values ranged from 69 ± 1.9 to 126 ± 3.2 µg/mL and from 107.01 ± 4.5 to 184.20 ± 5.7 µg/mL before and after cooking | [38] |
| (S)-malic acid | Ethanol and methanol extracts from *Flacourtia inermis* |        | IC$_{50}$ from 1021 to 1949 ppm | [40] |
| Syringic acid, o-coumaric acid and quercetin | Aqueous extract of *Psidium guajava* |        | before the exposure to gastric fluid 14410.60 ± 38 inhibited enzyme unit in µmol min$^{-1}$·g$^{-1}$ | [43] |
| - | *Argenantheum pinnatifidum* (leaves) | In vitro | IC$_{50}$ 1.55 ± 0.04 mg/mL | |
| - | *Argenantheum pinnatifidum* (flowers) | | IC$_{50}$ 2.18 ± 0.05 mg/mL | |
| - | *Artemisia argentea* (leaves) | | IC$_{50}$ 1.81 ± 0.03 mg/mL | |
| - | *Artemisia argentea* (flowers) | | IC$_{50}$ 2.48 ± 0.04 mg/mL | |
| - | *Helichrysum devium* (leaves) | | IC$_{50}$ 1.85 ± 0.06 mg/mL | |
| - | *Helichrysum devium* | | IC$_{50}$ 2.39 ± 0.03 mg/mL | |
| - | *Helichrysum melaleucum* (leaves) | | IC$_{50}$ 1.71 ± 0.02 mg/mL | |
| - | *Helichrysum melaleucum* (flowers) | | IC$_{50}$ 2.15 ± 0.05 mg/mL | |
| - | Ethyl acetate extracts pits from Tunisian date palm variety Kentichi | | IC$_{50}$ 25.4 ± 0.6 µg/mL | |
| - | Methanol extracts pits from Tunisian date palm variety Kentichi | | IC$_{50}$ 0.072 ± 0.003 µg/mL | |
| - | Ethanol extract of fresh *Euchema denticulatum* | 88% inhibition | | |
| - | *Saccharina japonica* fermented by *Monascus purpureus* | | IC$_{50}$ 0.98 ± 0.10 mg/mL | |
Table 5. Natural alpha-glucosidase inhibitors.

| Compound                                      | Source                                      | Method       | Results            | Reference |
|-----------------------------------------------|---------------------------------------------|--------------|--------------------|-----------|
| 2,4,6-tribromophenol                          | Purified from *Grateloupia elliptica*       | *Iodige okamure* | IC<sub>50</sub> 60.3 µM | [92]      |
| 2,4-dibromophenol                            | Purified from *Grateloupia elliptica*       |              | IC<sub>50</sub> 110.4 µM | [83]      |
| Diplolethhydroryxcarvalol (DPHC)              |                                             |              | IC<sub>50</sub> 0.16 mM | [83]      |
|                                             | Cladophora rupestris                        |              | Methanol (67%) and ethyl acetate (61%) extracts | [94]      |
|                                             |                                             |              | IC<sub>50</sub> = 19 µg/mL | [95]      |
|                                             |                                             |              | 76.02 ± 0.83% inhibition after 8 h of extraction | [96]      |
| 79.55 ± 3.08% inhibition after 8 h of extraction |                                             |              | IC<sub>50</sub> 1.2 ± 0.2 µg/mL. | [79]      |
|                                             |                                             |              | IC<sub>50</sub> 0.5 ± 0.1 µg/mL. | [79]      |
|                                             |                                             |              | IC<sub>50</sub> 2.5 ± 0.4 µg/mL. | [79]      |
| Kaempferol monoglucoside                      | Camelia sinensis                            | In vitro     | IC<sub>50</sub> 40.02 ± 4.61 µM | [80]      |
|                                             | Aqueous extracts of *Morinda lucida*        |              | IC<sub>50</sub> 2.00 mg/mL | [81]      |
|                                             | Acetone extracts from *Pieraluma nitida*    |              | IC<sub>50</sub> 3.00 µg/mL | [81]      |
|                                             | Ethanol-free extract of *Abutilon indicum*  |              | IC<sub>50</sub> = 207.13 mcg/mL. | [85]      |
|                                             | Aqueous methanol extracts of *Ononis angustissima* |              | IC<sub>50</sub> 0.94 mg/mL. | [86]      |
|                                             | N-butanol extracts of *Ononis angustissima* |              | IC<sub>50</sub> 0.99 mg/mL | [86]      |
|                                             | Root ethanolic extract of *Cissus cornifolia* |              | IC<sub>50</sub> 2.81 ± 0.97 µg/mL | [87]      |
|                                             | Aqueous root extract of *Cissus cornifolia* |              | IC<sub>50</sub> 37.48 ± 2.35 µg/mL | [87]      |
|                                             | Ethanolic extracts (70%) of *Hibiscus sabdariffa* |              | IC<sub>50</sub> 18.09 µg/mL | [88]      |
|                                             | Aqueous ethanicolic extract (70% v/v) of *Capsicum annuum* |              | 66% at 5 mg/mL | [89]      |
|                                             | Protein hydrolysate from *Andrias davidianus* |              | IC<sub>50</sub> 42 µg/mL | [90]      |
| Cys-Ser-Ser-Val                               |                                             |              | IC<sub>50</sub> 206 µg/mL | [78]      |
| Tyr-Ser-Ph-Arg                                |                                             |              | IC<sub>50</sub> 162 µg/mL | [78]      |
| Ser-Ala-Ala-Pro                               |                                             |              | IC<sub>50</sub> 66.90 µg/mL | [78]      |
| Pro-Gly-Gly-Pro                               |                                             |              | IC<sub>50</sub> 63.50 µg/mL | [78]      |
| Leu-Gly-Gly-Gly-Asn                           |                                             |              | IC<sub>50</sub> 42.93 µg/mL | [78]      |
| 5-methoxy-7-hydroxy-9,10-dihydro-1,4-phenanthrenequinone | Methanol extract of *Dendobium formosum* |              | IC<sub>50</sub> 126.88 ± 0.66µM | [24]      |
| Polyphenols                                   | Polyphenol rich extracts of *Phaeolus vulgaris* |              | IC<sub>50</sub> values ranged from 39.3 ± 4.4 to 74.13 ± 6.9 µg/mL and from 51 ± 7.7 to 122.1 ± 5.2 µg/mL before and after cooking | [38]      |
Table 5. Cont.

| Compound          | Source                                    | Method | Results                                                                 | Reference |
|-------------------|-------------------------------------------|--------|-------------------------------------------------------------------------|-----------|
| (S)-malic acid    | Ethanol and methanol extracts from *Flacourtia inermis* |        | IC50 from 549 to 710 ppm                                               | [40]      |
| Catechin          | Aqueous extract of *Psidium guajava*       |        | Before gastric fluid exposure 28.82 ± 0.02 inhibited enzyme unit in µmol·min⁻¹·g⁻¹ and after exposure 2.59 ± 0.06 inhibited enzyme unit in µmol·min⁻¹·g⁻¹ | [43]      |
| -                 | *Argyranthemum pinnatifidum* (leaves)     |        | IC₅₀ 0.57 ± 0.03 mg/mL                                                   | [44]      |
| -                 | *Argyranthemum pinnatifidum* (flowers)    |        | IC₅₀ 0.81 ± 0.02 mg/mL                                                   |           |
| -                 | *Saccharina japonica* fermented by *Monascus purpureus* |       | Maltose IC₅₀ 0.02 ± 0.07 mg/mL and sucrose IC₅₀ 0.08 ± 0.13 mg/mL         | [53]      |
| Polyphenols       | Winemaking generates by-products           |        | From 75.6 ± 2.5% to 93.7 ± 0.5%, samples treated with pronase and from 84.5 ± 0.5% to 96.5 ± 2.9% viscozyme | [48]      |
4. Conclusions

T2DM is a serious worldwide disease, occurring mainly because of an unhealthy lifestyle. Its prevention and control are achieved with changes in lifestyle, sometimes coupled with medication with several side effects and high costs associated. As a result, the search for new possible anti-hyperglycemic and anti-diabetic agents from natural sources without, or with less, side effects and at a low cost for the patient, has attracted interest from the scientific community, as shown in this review. The natural sources include extracts from plants, fruits, vegetables and specially from marine macro or microorganisms with bioactive compounds. Indeed, marine organisms such as seaweed from edible species have several compounds with modes of action involving specific mechanisms that can be employed in T2DM treatment. The bioactive compounds include polysaccharides and dietary fibers, fatty acids (MUFA and PUFA), and phenolic compounds. Taking into account that the development of T2DM takes time, the glycemic control can be prevented with the intake of healthy foods like seaweed for glycemic control as preventive measures. However, further research in the future is required to fully understand the anti-diabetic mechanisms of this type of food in the prevention and management of this pathology.

Author Contributions: Conceptualization A.M.D., M.P.G. and M.M.G.; investigation A.M.D.; methodology A.M.D.; writing—original draft A.M.D.; writing—review & editing A.M.D., M.P.G., S.B. and M.M.G.; project administration M.P.G. and M.M.G.; supervision M.P.G. and M.M.G.; visualization S.B. All authors have read and agree to the published version of the manuscript.

Funding: Fundação para a Ciência e a Tecnologia, Portugal: UID/MAR/04292/2019.

Acknowledgments: The authors thank FCT, Portugal, for financial support (UID/MAR/04292/2019). This work was also supported by project SmartBioR (CENTRO-01-0145-FEDER-000018, Integrated Programme SR&TD co-funded by Centro 2020 program, Portugal 2020, European Union, through the European Regional Development Fund).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sharifuddin, Y.; Chin, Y.X.; Lim, P.E.; Phang, S.M. Potential bioactive compounds from seaweed for diabetes management. *Mar. Drugs* 2015, 13, 5447–5491. [CrossRef] [PubMed]
2. Gago, A.S. Compostos Bioativos de Microalgas com Interesse no Tratamento da Diabetes. Master’s Thesis, Faculdade de Ciências e Tecnologia, Algarve, Portugal, 2016.
3. Motshakeri, M.; Ebrahimi, M.; Goh, Y.M.; Othman, H.H.; Hair-Bejo, M.; Mohamed, S. Effects of brown seaweed (*Sargassum polycystum*) extracts on kidney, liver, and pancreas of type 2 diabetic rat model. *Evid. Based Complment. Altern.* 2014, 2014, 1–11. [CrossRef] [PubMed]
4. Chakraborty, C.; Hsu, M.J.; Agoramoorthy, G. Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with sitagliptin and inhibitor diprotin-A. *Cell Biochem. Biophys.* 2014, 70, 907–922. [CrossRef] [PubMed]
5. Chatterjee, S.; Khunti, K.; Davies, M.J. Type 2 diabetes. *Lancet* 2017, 389, 2239–2251. [CrossRef]
6. Lee, S.H.; Jeon, Y.J. Anti-diabetic effects of brown algae derived phlorotannins marine polyphenols through diverse mechanisms. *Fitoterapia* 2013, 86, 129–136. [CrossRef]
7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010, 33, S62–S69. [CrossRef]
8. Hussain, A.; Claussen, B.; Ramachandran, A.; Williams, R. Prevention of type 2 diabetes: A review. *Diabetes Res. Clin. Pract.* 2007, 76, 317–326. [CrossRef]
9. Lee, H.J.; Kim, H.C.; Vitek, L.; Nam, C.M. Algae Consumption and Risk of Type 2 Diabetes: Korean National Health and Nutrition Examination Survey in 2005. *J. Nutr. Sci. Vitaminol.* 2010, 56, 13–18. [CrossRef]
10. Fowler, M.J. Microvascular and macrovascular complications of diabetes. *Clin. Diabetes* 2008, 26, 77–82. [CrossRef]
11. Duarte, R. Inibidores da DPP-4 (gliptinas)-10 anos depois (2007–2017). *RPD* 2017, 12, 62–67.
12. Liu, D.; Gao, H.; Tang, W.; Nie, S. Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus. *Ann. N. Y. Acad. Sci.* 2017, 1401, 28–36. [CrossRef] [PubMed]
13. Xu, H.L.; Kitajima, C.; Ito, H.; Miyazaki, T.; Baba, M.; Okuyama, T.; Okada, Y. Antidiabetic effect of polyphenols from brown alga *Ecklonia kurome* in genetically diabetic KK-AY mice. *Pharm. Biol.* 2012, 50, 393–400. [CrossRef] [PubMed]

14. Srinivasan, B.T.; Jarvis, J.; Khunti, K.; Davies, M.J. Recent advances in the management of type 2 diabetes *mellitus*: A review. *Postgrad. Med. J.* 2008, 84, 524–531. [CrossRef] [PubMed]

15. Meyer, K.A.; Kushi, L.H.; Jacobs, D.; Slavin, J.; Sellers, T.A.; Folsom, A.R. Carbohydrates, dietary fiber, and incidence of type 2 diabetes in a older woman. *Am. J. Clin. Nutr.* 2000, 71, 921–930. [CrossRef] [PubMed]

16. Forouhi, N.G.; Misra, A.; Mohan, V.; Taylor, R.; Yancy, W. Dietary and nutritional approaches for prevention and management of type 2 diabetes. *BMJ* 2018, 361, 1–9. [CrossRef]

17. Caprita, R.; Caprita, A.; Julean, C. Biochemical aspects of non-starch polysaccharides. *Sci. Pap. Anim. Sci. Biotechnol.* 2010, 43, 368–375.

18. Colberg, S.R.; Sigal, R.J.; Fernhall, B.; Regensteiner, J.G.; Blissmer, B.J.; Rubin, R.R.; Chasan-Taber, L.; Albright, A.L.; Braun, B. Exercise and type 2 diabetes. *Diabetes Care* 2010, 33, 147–167. [CrossRef]

19. Achari, A.E.; Jain, S.K. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. *Int. J. Mol. Sci.* 2017, 18, 1321. [CrossRef]

20. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R.E.; Tataranni, P.A. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. *J. Clin. Endocrinol. Metab.* 2001, 86, 1930–1935. [CrossRef]

21. Ríos, J.L.; Francini, F.; Schinella, G. Natural products for the treatment of type 2 diabetes mellitus. *Planta Med.* 2015, 81, 975–999. [CrossRef]

22. De la Garza, A.L.; Milagro, F.I.; Boque, N.; Campión, J.; Martínez, J.A. Natural inhibitors of pancreatic lipase as new players in obesity treatment. *Planta Med.* 2011, 77, 773–785. [CrossRef] [PubMed]

23. Roh, C.; Jung, U. Screening of Crude Plant Extracts with Anti-Obesity Activity. *Int. J. Mol. Sci.* 2012, 13, 1710–1719. [CrossRef] [PubMed]

24. Inthongkaew, P.; Chatsumpun, N.; Supasuteekul, C.; Kitisripanya, T.; Putalun, W.; Likhitwitayawuid, K.; Sritularak, B. α-Glucosidase and pancreatic lipase inhibitory activities and glucose uptake stimulatory effect of phenolic compounds from Dendrobium formosum. *Rev. Bras. Farmacogn.* 2017, 27, 480–487. [CrossRef]

25. Keskes, H.; Mnafgui, K.; Hamden, K.; Matuzawa, Y.; Pratley, R.E.; Tataranni, P.A. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. *J. Clin. Endocrinol. Metab.* 2001, 86, 1930–1935. [CrossRef]

26. Briones, A.T.; Chichioco-Hernandez, C.L. Lipase inhibitory activity of Carica papaya, Chrysophyllum cainito, Corchorus litorius, Cympogon citrates and Syzygium cumini extracts. *Food Res. Rep.* 2017, 2, 51–55. [CrossRef]

27. Moon, S.H.; Kim, M.Y. Phytochemical profile, antioxidant, antimicrobial and antipancreatic lipase activities of fermented Camellia japonica L leaf extracts. *Trop. J. Pharm. Res.* 2018, 17, 905–912. [CrossRef]

28. Jamous, R.M.; Abu-Zaitoun, S.Y.; Akkawi, R.J.; Ali-Shtayeh, M.S. Antiobesity and antioxidant potentials of selected Palestinian medicinal plants. *Evid. Based Complement. Altern. Med.* 2018, 1, 1–21. [CrossRef]

29. Glisan, S.L.; Grove, K.A.; Yennawar, N.H.; Lambert, J.D. Inhibition of pancreatic lipase by black tea theaflavins: Comparative enzymology and In silico modeling studies. *Food Chem.* 2017, 216, 296–300. [CrossRef]

30. Zhu, Y.T.; Ren, X.Y.; Yuan, L.; Liu, Y.M.; Liang, J.; Liao, X. Fast identification of lipase inhibitors in oolong tea by using lipase functionalised Fe3O4 magnetic nanoparticles coupled with UPLC–MS. *Food Chem.* 2015, 173, 521–526. [CrossRef]

31. Yu, H.; Dong, S.; Wang, L.; Yun, L. The effect of triterpenoid saponins on pancreatic lipase In vitro: Activity, conformation, kinetics, thermodynamics and morphology. *Biochem. Eng. J.* 2017, 125, 1–9. [CrossRef]

32. Oliveira, V.B.; Araújo, R.L.B.; Eisenberger, T.; Brandão, M.G.L. Chemical composition and inhibitory activities on dipeptidyl peptidase IV and pancreatic lipase of two underutilized species from the Brazilian Savannah: Oxalis cordata A.St.-Hil. and Xylopia aromatica (Lam.) Mart. *Food Res. Int.* 2018, 105, 989–995. [CrossRef] [PubMed]

33. Belfeki, H.; Mnasser, H.; Mondher, M. Antioxidant and anti-lipases activities In vitro of Mentha viridis and Eucalyptus globulus extracts. *Ind. Crop. Prod.* 2016, 89, 514–521. [CrossRef]

34. Buchhols, T.; Melzig, M.F. Medicinal plants traditionally used for treatment of obesity and diabetes mellitus-screening for pancreatic lipase and α-amylase inhibition. *Phytother. Res.* 2016, 30, 260–266. [CrossRef] [PubMed]
35. Etoundi, C.B.; Kuate, D.; Ngondi, J.L.; Oben, J. Anti-amylase, anti-lipase and antioxidant effects of aqueous extracts of some Cameroonian spices. *J. Nat. Prod.* 2010, 3, 165–171.

36. Maqsood, M.; Ahmed, D.; Atique, I.; Malik, W. Lipase inhibitory activity of *Lagenaria siceraria* fruit as a strategy to treat obesity. *Asian Pac. J. Trop. Biomed.* 2017, 10, 305–310. [CrossRef]

37. Liu, T.T.; He, X.R.; Xu, X.; Wu, X.B.; Qi, Y.X.; Huang, J.Z.; Chen, Q.H.; Chen, Q.X. Inhibitory mechan and molecular analysis of furoic acid and oxalic acid on lipase. *Int. J. Biol. Macromol.* 2018, 120, 1925–1934. [CrossRef]

38. Ombra, M.N.; d’Acierno, A.; Nazzaro, F.; Spigno, P.; Riccardi, R.; Zaccardelli, M.; Pane, C.; Coppola, R.; Fratianni, F. Alpha-amylase, a-glucosidase and lipase inhibiting activities of polyphenol-rich extracts from six common bean cultivars of Southern Italy, before and after cooking. *Int. J. Food Sci. Nutr.* 2018, 69, 824–834. [CrossRef]

39. Austin, C.; Stewart, D.; Allwood, J.W.; Mc Dougall, G.J. Extracts from the edible seaweed, *Ascosiphum nodosum*, inhibit lipase activity In vitro: Contributions of phenolic and polysaccharide components. *Food Funct.* 2018, 9, 502–510. [CrossRef]

40. Alakolanga, A.G.; Kumar, N.S.; Jayasinghe, L.; Fujimoto, Y. Antioxidant property and α-glucosidase, α-amylase and lipase inhibiting activities of *Flacourtia inermis* fruits: Characterization of malic acid as an inhibitor of the enzymes. *J. Food Sci. Technol.* 2015, 52, 8383–8388. [CrossRef]

41. Ikarashi, N.; Takeda, R.; Ito, K.; Ochiai, W.; Suigiyama, K. The inhibition of lipase and glucosidase activities by Acacia polyphenol. *Evid. Based Complement. Altern. Med.* 2011, 1, 1–8. [CrossRef]

42. Han, L.; Li, W.; Narimatsu, S.; Liu, L.; Fu, H.; Okuda, H.; Koike, K. Inhibitory effects of compounds isolated from fruit of *Fragaria mandshurica* on pancreatic lipase. *J. Nat. Med.* 2006, 61, 184–186. [CrossRef]

43. Simão, A.A.; Marques, T.R.; Marcussi, S.; Corrêa, A.D. Aqueous extract of *Psidium guajava* leaves: Phenolic compounds and inhibitory potential on digestive enzymes. *An. Acad. Bras. Cienc.* 2017, 89, 2155–2165. [CrossRef] [PubMed]

44. Spinola, V.; Castilho, P.C. Evaluation of *Asteraceae* herbal extracts in the management of diabetes and obesity. Contribution of caffeoylquinic acids on the inhibition of digestive enzymes activity and formation of advanced glycation end-products (In vitro). *Phytochemistry* 2017, 143, 29–35. [CrossRef] [PubMed]

45. Masmoudi-Allouche, F.; Touati, S.; Mnaefgui, K.; Gharsallah, N.; El Feki, A.; Allouche, N. Phytochemical profile, antioxidant, antibacterial, antidiabetic and anti-obesity activities of fruits and pits from date palm (*Phoenix dactylifera L.* grown in south of Tunisia). *J. Pharmacogn. Phytochem.* 2016, 5, 15–22.

46. Jang, D.S.; Lee, G.Y.; Kim, J.; Lee, J.; Kim, J.M.; Kim, J.Y. A New Pancreatic Lipase Inhibitor Isolated from the Roots of *Actinidia arguta*. *Arch. Pharm. Res.* 2008, 31, 666–670. [CrossRef]

47. Wan, L.H.; Jiang, X.L.; Liu, Y.M.; Hu, J.J.; Liann, J.; Liao, X. Screening of lipase inhibitors from *Scutellaria baicalensis* extract using lipase immobilized on magnetic nanoparticles and study on the inhibitory mechanism. *Anal. Bioanal. Chem.* 2016, 408, 2275–2283. [CrossRef]

48. de Camargo, A.C.; Regitano-d’Arce, M.A.B.; Biasoto, A.C.T.; Shahidi, F. Enzyme-assisted extraction of phenolics from winemaking by-products: Antioxidant potential and inhibition of α-glucosidase and lipase activities. *Food Chem.* 2016, 212, 395–402. [CrossRef]

49. Wong, X.; Madrid, A.M.; Traima, K.; Castillo, R.; Carrasco-Pozo, C.; Navarrete, P.; Beltrán, C.; Pastene, E.; Gotteland, M. Polyphenol extracts interfere with bacterial lipopolysaccharide In vitro and decrease postprandial endotoxia in human volunteers. *J. Funct. Foods* 2016, 26, 406–417. [CrossRef]

50. Balasubramaniam, V.; Mustar, S.; Khalid, N.M.; Rashid, A. Inhibitory activities of three Malaysian edible seaweeds on lipase and α-amylase. *J. Appl. Phycol.* 2013, 25, 441–445. [CrossRef]

51. Bitou, N.; Ninomiya, M.; Tsujita, T.; Okuda, H. Screening of lipase inhibitors from marine algae. *Lipids* 1999, 34, 441–445. [CrossRef]

52. Eom, S.H.; Lee, M.S.; Lee, E.W.; Kim, Y.M.; Kim, T.H. Pancreatic lipase inhibitory activity of phlorotannins isolated from *Eisenia bicyclus*. *Phytother. Res.* 2012, 27, 148–151. [CrossRef] [PubMed]

53. Suraiya, S.; Lee, J.M.; Cho, H.J.; Jang, W.J.; Kim, D.G.; Kim, Y.O.; Kong, I.S. *Monascus* spp. fermented brown seaweeds extracts enhance bio-functional activities. *Food Biosci.* 2018, 21, 90–99. [CrossRef]

54. Biriri, R.B.; Bhutani, K.K. Pancreatic lipase inhibitors from natural sources: Unexplored potential. *Drug Discov. Today* 2007, 12, 879–889. [CrossRef] [PubMed]

55. Buchholz, T.; Melzig, M.F. Polyphenolic compounds as pancreatic lipase inhibitors. *Planta Med.* 2015, 81, 771–783. [CrossRef]
56. Wilcox, M.D.; Brownlee, I.A.; Richardson, J.C.; Dettmar, P.W.; Pearson, J.P. The modulation of pancreatic lipase activity by alginates. *Food Chem.* 2014, 146, 479–484. [CrossRef]

57. Bower, A.M.; Real Hernandez, L.M.; Berhow, M.A.; de Mejia, E.G. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV. *J. Agric. Food Chem.* 2014, 62, 6147–6158. [CrossRef]

58. Zhang, L.; Jiang, C.S.; Gao, L.X.; Wang, Z.H.; Li, J.Y.; Li, J.; Li, X.W.; Guo, Y.W. Design, synthesis and In vitro activity of phidonamine B derivatives as novel PTP1B inhibitors with specific selectivity. *Bioorg. Med. Chem. Lett.* 2016, 26, 778–781. [CrossRef]

59. Huang, Q.H.; Lei, C.; Wang, P.P.; Li, J.Y.; Li, J.; Hou, A.J. Isoprenylated phenolic compounds with PTP1B inhibition from *Morus alba*. *Fitoterapia* 2017, 122, 138–143. [CrossRef]

60. Zhang, J.; Sasaki, T.; Li, W.; Nagata, K.; Higai, K.; Feng, F.; Wang, J.; Cheng, M.; Koike, K. Identification of caffeoylquinic acid derivatives as natural protein tyrosine phosphatase 1B inhibitors from *Artemisia princeps*. *Bioorg. Med. Chem. Lett.* 2018, 28, 1194–1197. [CrossRef]

61. Trinh, B.T.D.; Jäger, A.K.; Staerk, D. High-resolution inhibition profiling combined with HPLC-HRMS-SPE-NMR for identification of PTP1B inhibitors from Vietnamese plants. *Molecules* 2017, 22, 1228. [CrossRef]

62. Ezzat, S.M.; Bishbishy, M.H.E.; Habtemariam, S.; Salehi, B.; Sharifi-Rad, M.; Martins, N.; Sharifi-Rad, J. Looking at marine-derived bioactive molecules as upcoming anti-diabetic agents: A special emphasis on PTP1B inhibitors. *Molecules* 2018, 23, 3334. [CrossRef] [PubMed]

63. dos Reis, M.S.R. Inibidores da DPP-4: Uma Esperança na Nefropatia Diabética? Master’s Thesis, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal, 2015.

64. Chin, Y.X.; Lim, P.E.; Maggs, C.A.; Phang, S.M. Anti-diabetic potential of selected Malaysian seaweeds. *J. Appl. Physiol.* 2014, 27, 2137–2148. [CrossRef]

65. Unnikrishnan, P.S.; Suthindhiran, K.; Jayasri, M.A. Antidiabetic potential of marine algae by inhibiting key metabolic enzymes. *Front. Life Sci.* 2015, 8, 148–159. [CrossRef]

66. Power, O.; Nongonierma, A.B.; Jakeman, P.; FitzGerald, R.J. Food protein hydrolysates as a source od dipeptidyl peptidase for the management of type 2 diabetes. *Proc. Nutr. Soc.* 2014, 73, 34–46. [CrossRef] [PubMed]

67. Tulipano, G.; Sibilia, V.; Caroli, A.M.; Cocchi, D. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. *Peptides* 2011, 32, 835–838. [CrossRef] [PubMed]

68. Suman, R.K.; Mohanty, I.R.; Maheshwari, U.; Borde, M.K.; Deshmukh, Y.A. Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes-and metabolic syndrome-Induced changes in experimental rats. *Diabetes Metab. Syndr. Obes.* 2016, 9, 261–272. [CrossRef] [PubMed]

69. Lacroix, I.M.E.; Li-Chan, E.C.Y. Evaluation of the potential of dietary proteins as precursors of dipeptidyl peptidase IV inhibitors by an In silico approach. *J. Funct. Foods* 2012, 4, 403–422. [CrossRef]

70. Nongonierma, A.B.; FitzGerald, R.J. Dipeptidyl peptidase IV inhibitory and antioxidative properties of milk protein-derived dipeptides and hydrolysates. *Peptides* 2013, 39, 157–163. [CrossRef]

71. Fan, J.; Johnson, M.H.; Lila, M.A.; Yousef, G.; de Mejia, E.G. Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: Implications in diabetes management. *Evid. Based Complement. Altern. Med.* 2013, 1–13. [CrossRef]

72. Unnikrishnan, P.S.; Suthindhiran, K.; Jayasri, M.A. Inhibitory potential of *Turbinaria ornata* against key metabolic enzymes linked to diabetes. *Biomed. Res. Int.* 2014, 2014, 1–10. [CrossRef]

73. Pascual, I.; Lopéz, A.; Gómez, H.; Chappe, M. Screening of inhibitors of porcine dipeptidyl peptidase IV activity in aqueous extracts from marine organisms. *Enzyme. Microb. Technol.* 2007, 40, 414–419. [CrossRef]

74. Jao, C.L.; Hung, C.C.; Tung, Y.S.; Lin, P.Y.; Chen, M.C.; Hsu, K.C. The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes. *Biomedicine* 2015, 5, 9–15. [CrossRef] [PubMed]

75. Lacroix, I.M.E.; Li-Chan, E.C.Y. Food-derived dipeptidyl-peptidase IV inhibitors as a potential approach for glycemic regulation-current knowledge and future research considerations. *Trends Food Sci. Technol.* 2016, 54, 1–16. [CrossRef]

76. Pereira, L.; Neto, J.M. Marine Algae-Biodiversity, Taxonomy, Environmental Assessment, and Biotechnology, 1st ed.; CRC Press: Boca Raton, FL, USA; Taylor & Francis Group: Boca Raton, FL, USA, 2015; pp. 1–2.
77. Sun, Z.; Chen, F. Evaluation of green alga Chlorella pyrenoidosa for management of diabetes. J. Food Drug Anal. 2012, 20, 246–249.

78. Ramadhan, A.H.; Nawas, T.; Zhang, X. Purification and identification of a novel antidiabetic peptide from Chinese giant salamander (Andrias davidianus) protein hydrolysate against α-amylase and α-glucosidase. Int. J. Food Prop. 2018, 20, S3360–S3372. [CrossRef]

79. Yilmazer-Musa, M.; Griffith, A.M.; Michels, A.J.; Schneider, E.; Frei, B. Inhibition of α-amylase and α-glucosidase activity by tea and grape seed extracts and their constituent catechins. J. Agric. Food Chem. 2012, 60, 8924–8929. [CrossRef]

80. Hua, F.; Zhou, P.; Wu, H.Y.; Chu, G.X.; Xie, Z.W.; Bao, G.H. Inhibition of flavonoid glycosides from Lu’an GuaPian tea on α-glucosidase and α-amylase: Molecular docking and interaction mechanism. Food Funct. 2018, 9, 4173–4183. [CrossRef]

81. Kazeem, M.I.; Adamson, J.O.; Ogunwande, I.A. Modes of inhibition of α-amylase and α-glucosidase by aqueous extract of Morinda lucida benth leaf. Biomed. Res. Int. 2013, 2013, 1–6. [CrossRef]

82. Thilagam, E.; Parimaladevi, B.; Kumarappan, C.; Mandal, S.C. α-Glucosidase and α-amylase inhibitory activity of Senna surattensis. J. Acupunct. Meridian Stud. 2013, 6, 24–30. [CrossRef]

83. Kazeem, M.I.; Ogunbiiyi, J.V.; Ashafa, A.O.T. In vitro studies on the inhibition of α-amylase and α-glucosidase by leaf extracts of Picralima nitida (stafi). TJPR 2013, 12, 719–725. [CrossRef]

84. Hadrich, F.; Bouallagui, Z.; Junkyu, H.; Isoda, H.; Sayadi, S. The α-glucosidase and α-amylase enzyme inhibitory of hidroxtyrosol and oleuropein. J. Oleo Sci. 2015, 64, 835–843. [CrossRef] [PubMed]

85. Arce, F.J.V.; Concepcion, J.E.D.; Mayol, K.M.C.; See, G.L.L. In vitro α-amylase and α-glucosidase inhibition activity of tabing Abutilon indicum (Linn 1836) root extracts. IJTPR 2016, 8, 391–396.

86. Laoufi, H.; Nabila, B.; Adjdir, S.; Djaziri, R. In vitro α-amylase and α-glucosidase inhibitory activity of Ononis angustissima extracts. J. Appl. Pharm. Sci. 2017, 7, 191–198. [CrossRef]

87. Chipiti, T.; Ibrahim, M.A.; Singh, M.; Islam, M.S. In vitro α-amylase and α-glucosidase inhibitory and cytotoxic activities of extracts from Cissus cornifolia planch parts. Pharmacogn. Mag. 2017, 13, S329–S333. [CrossRef]

88. Gondokesumo, M.E.; Kusuma, H.S.W.; Widowati, W. α-/β-glucosidase and α-amylase inhibitory activities of roselle ( Hibiscus sabdariffa L.) ethanol extract. MCBS 2017, 1, 34–40. [CrossRef]

89. Watcharachaisoponsiri, T.; Sornchan, P.; Charoenkiatkul, S.; Suttisansanee, U. The α-glucosidase and α-amylase inhibitory activity from different chili pepper extracts. Int. Food Res. J. 2016, 23, 1439–1445.

90. Kalita, D.; Holm, D.G.; LaBarbera, D.V.; Pettrash, J.M.; Jayanty, S.S. Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato polyphenolic compounds. PLoS ONE 2018, 13, e0191025. [CrossRef]

91. Okada, Y.; Ishimaru, A.; Suzuki, R.; Okuyama, T. A new phloroglucinol derivative from the brown alga Ishige okamure and aldose reductase by potato polyphenolic compounds. Phytochemistry 2008, 69, 2820–2825. [CrossRef]

92. Heo, S.J.; Hwang, J.Y.; Choi, J.I.; Han, J.S.; Kim, H.J.; Jeon, Y.J. Diphlorethohydroxycarmalol isolated from Ishige okamure, a brown alga, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. J. Agric. Food Chem. 2009, 615, 252–256. [CrossRef]

93. Krish, S.; Das, A. In-vitro bioactivity of marine seaweed, Cladophora rupestris. Int. J. Pharma Bio Sci. 2014, 5, B898–B908. [CrossRef]

94. Nwosu, F.; Morris, J.; Lund, V.A.; Stewart, D.; Ross, H.A.; McDougall, G.J. Anti-proliferative and potential anti-diabetic effects of phenolic-rich extracts from edible marine algae. Food Chem. 2011, 126, 1006–1012. [CrossRef]

95. Reka, P.; Banu, T.; Seethalakshmi, M. Alpha amylase and alpha glucosidase inhibition activity of selected edible seaweeds from south coast area of India. Int. J. Pharm. Sci. 2017, 9, 64–68. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).